



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Clozapine dose for schizophrenia (Review)

Subramanian S, Völlm BA, Huband N

Subramanian S, Völlm BA, Huband N.  
Clozapine dose for schizophrenia.  
*Cochrane Database of Systematic Reviews* 2017, Issue 6. Art. No.: CD009555.  
DOI: [10.1002/14651858.CD009555.pub2](https://doi.org/10.1002/14651858.CD009555.pub2).

[www.cochranelibrary.com](http://www.cochranelibrary.com)

**Clozapine dose for schizophrenia (Review)**  
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**WILEY**

**TABLE OF CONTENTS**

ABSTRACT .....	1
PLAIN LANGUAGE SUMMARY .....	2
SUMMARY OF FINDINGS .....	4
BACKGROUND .....	9
Figure 1. ....	11
OBJECTIVES .....	11
METHODS .....	11
RESULTS .....	17
Figure 2. ....	18
Figure 3. ....	20
Figure 4. ....	21
DISCUSSION .....	24
AUTHORS' CONCLUSIONS .....	26
ACKNOWLEDGEMENTS .....	27
REFERENCES .....	28
CHARACTERISTICS OF STUDIES .....	32
DATA AND ANALYSES .....	41
Analysis 1.1. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 1 Mental state: Average endpoint score (BPRS-A, high = poor) - medium term. ....	42
Analysis 1.2. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 2 Adverse effects: 1a. Weight - BMI - short term. ....	42
Analysis 1.3. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 3 Adverse effects: 1b. Weight - weight gain. ....	42
Analysis 1.4. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 4 Adverse effects: 1c. Weight - body weight at endpoint - short term. ....	43
Analysis 1.5. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 5 Adverse effects: 2a. Metabolic - blood glucose - short term. ....	43
Analysis 1.6. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 6 Adverse effects: 2b. Metabolic - lipid profile - short term. ....	44
Analysis 1.7. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 7 Leaving the study early. ....	45
Analysis 2.1. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 1 Mental state: 1a. Average endpoint score (BPRS-A, high = poor) - medium term. ....	47
Analysis 2.2. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 2 Adverse effects: 1a. Weight - BMI - short term. ....	47
Analysis 2.3. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 3 Adverse effects: 1b. Weight - weight gain. ....	47
Analysis 2.4. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 4 Adverse effects: 1c. Weight - body weight at endpoint - short term. ....	48
Analysis 2.5. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 5 Adverse effects: 2a. Metabolic - blood glucose - short term. ....	48
Analysis 2.6. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 6 Adverse effects: 2b. Metabolic - lipid profile - short term. ....	48
Analysis 2.7. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 7 Leaving the study early. ....	49
Analysis 3.1. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 1 Mental state: 1a. Clinically important response as (BPRS score > 30% change). ....	52
Analysis 3.2. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 2 Mental state: 1b. Average endpoint score (BPRS-A total, high = poor). ....	53
Analysis 3.3. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 3 Mental state: 1c. Average endpoint score (BPRS-A subscores, high = poor) - short term. ....	53
Analysis 3.4. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 4 Mental state: 1e. Clinical improvement, clinician assessed. ....	54

Analysis 3.5. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 5 Adverse effects: 1a. Weight - BMI - short term. ....	54
Analysis 3.6. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 6 Adverse effects: 1b. Weight - weight gain. ....	54
Analysis 3.7. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 7 Adverse effects: 1c. Weight - body weight at endpoint - short term. ....	55
Analysis 3.8. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 8 Adverse effects: 2a. Metabolic - blood glucose - short term. ....	55
Analysis 3.9. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 9 Adverse effects: 2b. Metabolic - lipid profile - short term. ....	56
Analysis 3.10. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 10 Adverse effects: 3. Various effects - short term. ....	56
Analysis 3.11. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 11 Adverse effects: 4. Average endpoint scores (TESS, high = poor) - short term. ....	57
Analysis 3.12. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 12 Leaving the study early. ....	58
ADDITIONAL TABLES .....	58
APPENDICES .....	59
HISTORY .....	59
CONTRIBUTIONS OF AUTHORS .....	59
DECLARATIONS OF INTEREST .....	60
SOURCES OF SUPPORT .....	60
DIFFERENCES BETWEEN PROTOCOL AND REVIEW .....	60
INDEX TERMS .....	60

[Intervention Review]

# Clozapine dose for schizophrenia

Selvizhi Subramanian<sup>1</sup>, Birgit A Völm<sup>2</sup>, Nick Huband<sup>2</sup>

<sup>1</sup>Department of Psychiatry, Morecambe Community Mental Health Team, Morecambe, UK. <sup>2</sup>Division of Psychiatry & Applied Psychology, University of Nottingham Innovation Park, Nottingham, UK

**Contact:** Nick Huband, Division of Psychiatry & Applied Psychology, University of Nottingham Innovation Park, Institute of Mental Health, Triumph Road, Nottingham, NG7 2TU, UK. [nick.huband@nottingham.ac.uk](mailto:nick.huband@nottingham.ac.uk).

**Editorial group:** Cochrane Schizophrenia Group.

**Publication status and date:** New, published in Issue 6, 2017.

**Citation:** Subramanian S, Völm BA, Huband N. Clozapine dose for schizophrenia. *Cochrane Database of Systematic Reviews* 2017, Issue 6. Art. No.: CD009555. DOI: [10.1002/14651858.CD009555.pub2](https://doi.org/10.1002/14651858.CD009555.pub2).

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Schizophrenia and related disorders such as schizophreniform and schizoaffective disorder are serious mental illnesses characterised by profound disruptions in thinking and speech, emotional processes, behaviour and sense of self. Clozapine is useful in the treatment of schizophrenia and related disorders, particularly when other antipsychotic medications have failed. It improves positive symptoms (such as delusions and hallucinations) and negative symptoms (such as withdrawal and poverty of speech). However, it is unclear what dose of clozapine is most effective with the least side effects.

### Objectives

To compare the efficacy and tolerability of clozapine at different doses and to identify the optimal dose of clozapine in the treatment of schizophrenia, schizophreniform and schizoaffective disorders.

### Search methods

We searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (August 2011 and 8 December 2016).

### Selection criteria

All relevant randomised controlled trials (RCTs), irrespective of blinding status or language, that compared the effects of clozapine at different doses in people with schizophrenia and related disorders, diagnosed by any criteria.

### Data collection and analysis

We independently inspected citations from the searches, identified relevant abstracts, obtained full articles of relevant abstracts, and classified trials as included or excluded. We included trials that met our inclusion criteria and reported useable data. For dichotomous data, we calculated the relative risk (RR) and the 95% confidence interval (CI) on an intention-to-treat basis based on a random-effects model. For continuous data, we calculated mean differences (MD) again based on a random-effects model. We assessed risk of bias for included studies and created 'Summary of findings' tables using GRADE.

### Main results

We identified five studies that could be included. Each compared the effects of clozapine at very low dose (up to 149 mg/day), low dose (150 mg/day to 300 mg/day) and standard dose (301 mg/day to 600 mg/day). Four of the five included studies were based on a small number of participants. We rated all the evidence reported for the main outcomes of interest as low or very low quality. No data were available for the main outcomes of global state, service use or quality of life.

*Very low dose compared to low dose*

### Clozapine dose for schizophrenia (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

We found no evidence of effect on mental state between low and very low doses of clozapine in terms of average Brief Psychiatric Rating Scale-Anchored (BPRS-A) endpoint score (1 RCT, n = 31, MD 3.55, 95% CI -4.50 to 11.60, very low quality evidence). One study found no difference between groups in body mass index (BMI) in the short term (1 RCT, n = 59, MD -0.10, 95% CI -0.95 to 0.75, low-quality evidence).

#### *Very low dose compared to standard dose*

We found no evidence of effect on mental state between very low doses and standard doses of clozapine in terms of average BPRS-A endpoint score (1 RCT, n = 31, MD 6.67, 95% CI -2.09 to 15.43, very low quality evidence). One study found no difference between groups in BMI in the short term (1 RCT, n = 58, MD 0.10, 95% CI -0.76 to 0.96, low-quality evidence)

#### *Low dose compared to standard dose*

We found no evidence of effect on mental state between low doses and standard doses of clozapine in terms of both clinician-assessed clinical improvement (2 RCTs, n = 141, RR 0.76, 95% CI 0.36 to 1.61, medium-quality evidence) and clinically important response as more than 30% change in BPRS score (1 RCT, n = 176, RR 0.93, 95% CI 0.78 to 1.10, medium-quality evidence). One study found no difference between groups in BMI in the short term (1 RCT, n = 57, MD 0.20, 95% CI -0.84 to 1.24, low-quality evidence).

We found some evidence of effect for other adverse effect outcomes; however, the data were again limited.

#### *Very low dose compared to low dose*

There was limited evidence that serum triglycerides were lower at low-dose clozapine compared to very low dose in the short term (1 RCT, n = 59, MD 1.00, 95% CI 0.51 to 1.49).

#### *Low dose compared to standard dose*

Weight gain was lower at very low dose compared to standard dose (1 RCT, n = 27, MD -2.70, 95% CI -5.38 to -0.02). Glucose level one hour after meal was also lower at very low dose (1 RCT, n = 58, MD -1.60, 95% CI -2.90 to -0.30). Total cholesterol levels were higher at very low compared to standard dose (1 RCT, n = 58, MD 1.00, 95% CI 0.20 to 1.80).

#### *Low dose compared to standard dose*

There was evidence of fewer adverse effects, measured as lower TESS scores, in the low-dose group in the short term (2 RCTs, n = 266, MD -3.99, 95% CI -5.75 to -2.24); and in one study there was evidence that the incidence of lethargy (RR 0.77, 95% CI 0.60 to 0.97), hypersalivation (RR 0.70, 95% CI 0.57 to 0.84), dizziness (RR 0.56, 95% CI 0.39 to 0.81) and tachycardia (RR 0.57, 95% CI 0.45 to 0.71) was less at low dose compared to standard dose.

### **Authors' conclusions**

We found no evidence of effect on mental state between standard, low and very low dose regimes, but we did not identify any trials on high or very high doses of clozapine. BMI measurements were similar between groups in the short term, although weight gain was less at very low dose compared to standard dose in one study. There was limited evidence that the incidence of some adverse effects was greater at standard dose compared to lower dose regimes. We found very little useful data and the evidence available is generally of low or very low quality. More studies are needed to validate our findings and report on outcomes such as relapse, remission, social functioning, service utilisation, cost-effectiveness, satisfaction with care, and quality of life. There is a particular lack of medium- or long-term outcome data, and on dose regimes above the standard rate.

## **PLAIN LANGUAGE SUMMARY**

### **Clozapine dose in schizophrenia**

*Background:* Schizophrenia is a severe mental illness that affects thinking and perception. People with schizophrenia often experience profound disruptions in their speech, emotional processes, behaviour and sense of self. Antipsychotic medication can be a helpful treatment for schizophrenia; however, taking antipsychotic medication can have unpleasant effects. Clozapine is an antipsychotic drug that can be useful in treating schizophrenia, particularly when other antipsychotic medications have not worked. It is unclear, however, what dose of clozapine is most effective with the least side effects. This review investigates the effects of receiving clozapine at four different dose levels (high dose, standard dose, low dose, very low dose).

*Searching:* An electronic search for studies that randomised people with schizophrenia to receive different doses of clozapine was run in August 2011 and again on 8 December 2016.

*Results:* We found five studies with 452 participants which met our inclusion criteria. Each compared the effects of clozapine at very low dose (up to 149 mg/day), low dose (150 mg/day to 300 mg/day) and standard dose (301 mg/day to 600 mg/day). None of the studies examined the effects of clozapine at higher than the standard dose. There was nothing to choose between standard, low and very low doses in terms of body mass index (BMI) measurements in the short term. However, weight gain was greater in those receiving the standard

dose compared to those receiving the low dose. The incidence of unpleasant side effects (which included feeling lethargic, producing too much saliva, and feeling dizzy) was less at low dose compared to standard dose.

*Quality of evidence:* For main outcomes the quality was low or very low.

*Conclusions:* We found no evidence that might indicate the best dose of clozapine for patients with schizophrenia. Careful consideration has to be given to balancing the advantages and disadvantages of different doses in relation to weight gain and other side effects. Overall measurements of BMI were similar between groups; however, some side effects appear to be lower at lower doses. Overall, this review highlights the lack of evidence-based information available for addressing the question of what dose of clozapine is most effective with the least side effects. There is a need for large, well-designed and well-reported randomised clinical trials to address this question. There is a particular need for such trials to look at longer-term outcomes, and to examine the effects of clozapine when given at greater than the standard dose.

## SUMMARY OF FINDINGS

Summary of findings for the main comparison. Clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day) for schizophrenia

### CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150-300 mg/day) for schizophrenia

**Patient or population:** patients with schizophrenia

**Settings:**

**Intervention:** Clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day)				
<b>Global state: clinically important response, as defined by individual studies</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.
<b>Mental state: clinically important response, as defined by individual studies *</b>  Follow-up: 16 weeks		The mean clinical response: mental state - average scores - medium term endpoint (BPRS-A, high = worse) in the intervention group was <b>3.55 higher</b> (4.50 to 11.60 higher)		31 (1 study)	⊕⊕⊕⊕ <b>very low</b> 1,2,3	* Pre-defined outcome not reported: Mental state measured as average endpoint scores (BPRS-A, high = worse).
<b>Functioning: clinically important change in general functioning, as defined by individual studies</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.
<b>Adverse effect: clinically important adverse effect (weight - BMI)</b> Follow-up: 6 weeks		The mean adverse effect - any clinically important specific adverse effects - BMI in the intervention group was <b>0.1 lower</b> (0.95 lower to 0.75 higher)		59 (1 study)	⊕⊕⊕⊕ <b>low</b> 2,3	

<b>Service use: number of days hospitalised</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.
<b>Service use: time to hospitalisation</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.
<b>Quality of life: clinically important change in general quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** Confidence interval

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup> Risk of bias: rated as 'serious' (downgraded by 1) due to attrition bias, reporting bias, and sponsorship by Novartis Pharmaceuticals.

<sup>2</sup> Indirectness: rated 'serious' (downgraded by 1) as proxy measure of pre-defined outcome

<sup>3</sup> Imprecision: rated 'serious' (downgraded by 1) as only one study providing data, small number of participants (less than 200)

## Summary of findings 2. Clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia

### CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day) for schizophrenia

**Patient or population:** patients with schizophrenia

**Settings:**

**Intervention:** Clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	<b>Clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day)</b>				





<b>Global state: clinically important response, as defined by individual studies</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.
<b>Mental state: clinically important response, as defined by individual studies *</b> Follow-up: 16 weeks		The mean clinical response: mental state - average scores - medium term endpoint (BPRS-A, high = worse) in the intervention group was <b>6.67 higher</b> (2.09 to 15.43 higher)		31 (1 study)	⊕⊕⊕⊕ <b>very low</b> 1,2,3	* Pre-defined outcome not reported: Mental state measured as average endpoint scores (BPRS-A, high = worse).
<b>Functioning: clinically important change in general functioning, as defined by individual studies</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.
<b>Adverse effect: clinically important adverse effect (weight - BMI)</b> Follow-up: 6 weeks		The mean adverse effect - any clinically important specific adverse effects - BMI in the intervention group was <b>0.1 higher</b> (0.76 lower to 0.96 higher)		58 (1 study)	⊕⊕⊕⊕ <b>low</b> 2,3	
<b>Service use: number of days hospitalised</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.
<b>Service use: time to hospitalisation</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.
<b>Quality of life: clinically important change in general quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).  
**CI:** Confidence interval;

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>1</sup> Risk of bias: rated as 'serious' (downgraded by 1) due to attrition bias, reporting bias, and sponsorship by Novartis Pharmaceuticals.

<sup>2</sup> Indirectness: rated 'serious' (downgraded by 1) as proxy measure of pre-defined outcome

<sup>3</sup> Imprecision: rated 'serious' (downgraded by 1) as only one study providing data, small number of participants (less than 200)

### Summary of findings 3. Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia

**Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia**

**Patient or population:** patients with schizophrenia

**Settings:**

**Intervention:** Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day)				
<b>Global state: clinically important response, as defined by individual studies</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.
<b>Mental state: clinically important response in mental state</b> BPRS score >30% change Follow-up: 6 weeks	<b>Low<sup>1</sup></b>		<b>RR 0.93</b> (0.78 to 1.1)	176 (1 study)	⊕⊕○○ low 1,3	
	<b>200 per 1000</b>	<b>186 per 1000</b> (156 to 220)				
	<b>Moderate<sup>1</sup></b>					
	<b>500 per 1000</b>	<b>465 per 1000</b> (390 to 550)				
	<b>High<sup>1</sup></b>					
	<b>800 per 1000</b>	<b>744 per 1000</b> (624 to 880)				
<b>Functioning: clinically important change in general functioning, as defined by individual studies</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.



<b>Adverse effect: clinically important adverse effect ( weight - BMI)</b> Follow-up: 6 weeks		The mean adverse effect - any clinically important specific adverse effects - BMI in the intervention group was <b>0.2 higher</b> (0.84 lower to 1.24 higher)		57 (1 study)	⊕⊕○○ <b>low</b> 2,3	
<b>Service use: number of days hospitalised</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.
<b>Service use: time to hospitalisation</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.
<b>Quality of life: clinically important change in general quality of life</b>	See comment	See comment	Not estimable	0 (0)	See comment	No study reported this outcome.

\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** Confidence interval; **RR:** Risk ratio;

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

1 Risk of bias rated as 'serious' (downgraded by 1) as allocation concealment, blinding status and trial sponsorship unclear

2 Indirectness: rated 'serious' (downgraded by 1) as proxy measure of pre-defined outcome

3 Imprecision: rated as 'serious' (downgraded by 1) as only one study providing data, small number of participants (less than 200)

## BACKGROUND

Schizophrenia is a serious mental illness characterised by profound disruptions in thinking and speech, emotional processes, behaviour and sense of self (WHO 2013). It can have great impact in terms of both human suffering and societal expenditure (van Os 2009). It is among the world's top ten causes of long-term disability, leading to problems in social and occupational functioning and self-care (Meuser 2004). Before the introduction of clozapine, doctors largely relied on first generation (typical) antipsychotics, such as chlorpromazine, to control persisting symptoms and to prevent further exacerbations or relapse of illness (Kane 1990). Clozapine is the first second generation (atypical) antipsychotic drug introduced to the market. Arnt suggested that second generation antipsychotics are those that do not cause movement disorders (catalepsy) in rats at clinically effective doses (Arnt 1998). When clozapine was introduced it proved to be superior in controlling treatment-resistant illness, with fewer extrapyramidal side effects (EPSEs) than typical antipsychotics such as chlorpromazine (Kane 1988). However, clozapine was largely withdrawn from use in 1975 following the death of some patients due to the development of agranulocytosis. This withdrawal, however, was not followed worldwide. For example, Scandinavia, Germany and China continued to use clozapine. Subsequent studies demonstrated that clozapine could be administered safely when patients are carefully monitored for side effects such as agranulocytosis (Kane 1988; Naheed 2001). Following this, clozapine was reintroduced in the USA in 1990 with hopes that it would improve quality of life, cognitive functioning and movement disorders, and also reduce negative symptoms such as poverty of speech, blunting of affect, lack of volition and social withdrawal in the management of treatment-resistant schizophrenia. During this reintroduction, some safeguards were put in place; for example, clozapine is recommended to be used only in treatment-resistant schizophrenia along with regular monitoring for side effects such as agranulocytosis.

### Description of the condition

#### 1. Schizophrenia

WHO 2013 estimates that about 24 million people worldwide are affected by schizophrenia. The symptoms typically emerge in late adolescence or early adulthood. It is unclear as to what exactly causes schizophrenia, but both genetic and environmental factors are thought to play a role. WHO 2013 identified a low incidence of 3 per 100,000, whereas McGrath 2008 identified the median incidence of schizophrenia as 15.2 per 100,000 people. Saha 2005 found no significant difference in prevalence between urban, rural, and mixed sites. The prevalence of schizophrenia in migrants is higher compared to native-born individuals and is lower in poorer countries than in richer countries. Saha 2005 identified the median point prevalence of schizophrenia (the proportion of people who suffer from schizophrenia at a specific point in time) as 4.6 per 1000; the median lifetime prevalence for persons (the number of people in the population who have ever manifested the disease) was 4.0 per 1000; and the lifetime morbid risk (the likelihood of a particular individual developing schizophrenia in their lifetime) as 7.2 per 1000. Acute schizophrenia predominantly manifests itself with positive symptoms such as abnormal experiences; these include abnormal perceptions in the absence of a stimulus (hallucinations), false fixed beliefs (delusions), and disordered thinking. Chronic schizophrenia typically manifests itself with negative symptoms.

Though there is no complete agreement as to the specification of negative symptoms, it is generally agreed that they include poverty of speech, blunting of affect, lack of volition and social withdrawal (Gelder 2001). More than 50% of people with schizophrenia are not receiving appropriate care and about 90% of people with untreated schizophrenia live in developing countries (WHO 2013). Most cases of schizophrenia can be treated and those affected can lead a productive life and be integrated in society. The incidence of treatment resistance in schizophrenia is about 20% (Kerwin 2005). Clozapine reduces psychotic symptoms in 30% to 60% of such schizophrenia patients who have failed to respond to adequate trials of other antipsychotics (Buchanan 1995).

#### 2. Schizophreniform disorder

According to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, schizophreniform disorder is a condition with symptoms similar to schizophrenia but lasting less than six months (DSM-IV). In 1937 and 1939, follow-up studies were undertaken on patients who initially presented with symptoms similar to schizophrenia. Two different outcomes were identified in those patients. One group, whose symptoms were typical of schizophrenia, were identified as having a poor prognosis. The other group, whose symptoms were similar to those of schizophrenia but who had prominent affective symptoms, had a better outcome; Langfeldt introduced the concept of schizophreniform psychoses to describe this latter group (Noreik 1967; Guldberg 1991). Langfeldt's original schizophreniform cases were reviewed by other researchers using DSM-III and International Statistical Classification of Diseases and Related Health Problems, Ninth Revision (ICD-9) criteria. They concluded that most of the original schizophreniform cases described by Langfeldt possibly appeared to more closely resemble affective disorders with psychoses, rather than schizophrenia-like illness (Bergem 1990; Guldberg 1991). DSM-IV uses schizophreniform disorder to define a disorder that would otherwise meet the diagnostic criteria for schizophrenia but lasts less than six months (Gelder 2001). There are currently no reliable data on prevalence rates of schizophreniform disorder (Kaplan 2005). Treatment is similar to that of schizophrenia. Good prognostic factors for schizophreniform illness include episodic illness, recurrent course and a family history of mood disorders (Benazzi 2003).

#### 3. Schizoaffective disorder

In 1933 Jacob Kasanin coined the term schizoaffective psychosis (Kasanin 1933). Schizoaffective psychosis can be considered as a syndrome on the continuum between schizophrenia and mood disorders (such as depression and bipolar affective disorder) and presents with symptoms of both these illnesses (Danileviciute 2002). ICD-10 considers schizoaffective disorder as an episodic disorder in which both affective and schizophrenic symptoms are prominent but which does not justify a diagnosis of either schizophrenia or a depressive or manic episode. Studies on schizoaffective disorder suggest that it is relatively common in clinical settings. Among admissions to inpatient mental health facilities for functional psychosis, 10% to 30% comprise schizoaffective disorder. The lifetime prevalence of schizoaffective disorder is estimated to be between 0.5% and 0.8% and the illness typically presents with an episodic course (Azorin 2005). Psychotic features may include both positive and negative symptoms along with affective symptoms. Outcome is predicted by premorbid functioning, number of past episodes, persistence of psychotic

features and degree of cognitive impairment. [Vieta 2010](#) suggests that bipolar-type schizoaffective illness can be treated with second generation antipsychotics, either alone or in conjunction with a mood stabiliser. The depressive type of schizoaffective disorder can be treated with a second generation antipsychotic in conjunction with either an antidepressant or a mood stabiliser. Electroconvulsive therapy (ECT) can be considered in refractory cases. Prognosis appears to be better than for schizophrenia, but worse than for affective disorder ([Azorin 2005](#)).

### Description of the intervention

Prescribing of clozapine requires a number of preparatory steps. For example, before initiation of clozapine a base line physical examination should be performed with an ECG and base line blood tests, including full blood count. Patients must be registered with the clozapine patient monitoring services, and full blood count must be monitored once a week for the first 18 weeks, thereafter fortnightly for 34 weeks and then once in every four weeks for the period of time clozapine is taken. For adults over 16 years of age, clozapine should be started at a very low dose, e.g. 12.5 mg once or twice a day. On the second day, 25 mg to 50 mg is given, and, if well tolerated, the dose can be gradually increased in steps of 25 mg to 50 mg daily over 14 to 21 days up to 300 mg daily in divided doses. If necessary, the dose can be increased further. Elderly people may need slower titration. During initiation and titration, pulse and blood pressure (in standing and lying position) should be monitored regularly to identify persistent tachycardia and postural hypotension. If clozapine, for whatever reason, was omitted for a period of 48 hours, it should be restarted from lowest dose and titrated upwards. Adverse effects of clozapine include constipation, troublesome hypersalivation, tachycardia, ECG changes, hypertension, drowsiness, dizziness, headache, tremor, seizures, fatigue, impaired temperature regulation, urinary incontinence, urinary retention, leukopenia, eosinophilia, leucocytosis, and, less commonly, agranulocytosis, and other cardiovascular and respiratory side effects ([BNF 2012](#)).


### Accessibility of clozapine

Upon reintroduction of clozapine in the USA in 1990, clozapine was recommended to be used only in treatment-resistant schizophrenia, along with regular monitoring for side effects such as agranulocytosis. The British National Formulary currently recommends clozapine be used only in "schizophrenia (including

psychosis in Parkinson's disease) in patients unresponsive to, or intolerant of, conventional antipsychotic drugs" ([BNF 2012](#)). The National Institute for Health and Care Excellence recommends clozapine in people suffering from schizophrenia who did not respond adequately to sequential use of adequate doses of at least two different antipsychotic drugs, at least one of which should be a non-clozapine second-generation antipsychotic ([NICE](#)). Clozapine is made available only through the manufacturer's proprietary monitoring system, and all the UK manufacturers of clozapine such as Novartis (Clozaril), Merz (Denzapine), and Teva (Zaponex) require that the patients, prescribers and supplying pharmacists be registered with their relevant patient monitoring service. Through shared care arrangements with local community pharmacies dispensing clozapine, it is possible in the UK to initiate clozapine treatment in the community after registration with the patient monitoring services is completed ([CMHP](#)). However, general practitioners generally do not prescribe clozapine in the UK. [Aitchison 1997](#) suggested that the costs of prescribing clozapine could be recouped on savings in future inpatient care. [Wang 2004](#) indicated that if clozapine was made available as a first-line antipsychotic, it might possibly lead to small gains in life expectancy, at moderate but acceptable costs. [Kane 2011](#) opined that clozapine still remains strikingly under-utilised and that many practitioners across the world and across different clinical settings do not use clozapine even when indicated.

### How the intervention might work

Clozapine ([Figure 1](#)) was the first atypical antipsychotic to show definite benefit in treatment of patients where symptoms failed to respond to typical agents. Clozapine has the highest affinity for dopamine D<sub>4</sub>, 5-HT<sub>1C</sub>, 5-HT<sub>2</sub>, alpha 1, muscarinic and histamine H<sub>1</sub> receptors, but moderate affinity is also seen for many other receptor subtypes ([Coward 1992](#)). Clozapine causes fewer extrapyramidal side effects (EPSEs) than typical antipsychotics ([Kane 1988](#)). Clozapine appears to be more active at the limbic site than the striatal site and this might explain its low extrapyramidal side effect profile. It is metabolized mainly in the liver. Norclozapine is an active metabolite of clozapine. Monitoring the plasma levels of clozapine and norclozapine helps to assess compliance. It is suggested that the therapeutic response is associated with clozapine blood levels between 200 ng/ml and 400 ng/ml ([Kronig 1995](#)). Chemicals that affect cytochrome enzymes can reduce or increase plasma clozapine concentration.

**Figure 1. Clozapine structure**

### Why it is important to do this review

Different guidelines suggest different dosing for clozapine. For example, [BNF 2012](#) recommends a usual dose of 200 mg/day to 450 mg/day and the maximum daily dose of 900 mg. Merz, the UK manufacturer of Denzapine, also advises the prescription of clozapine at a dose between 200 mg/day and 450 mg/day, with maximum doses up to 900 mg/day. Novartis, the UK manufacturer of Clozaril, suggests that while many patients may respond adequately at doses between 300 mg/day and 600 mg/day, it may be necessary to raise the dose to the 600 mg/day to 900 mg/day range to obtain an acceptable response. [Kaplan 2005](#) suggests that daily doses between 250 mg/day and 450 mg/day are usually considered adequate and daily dosage above 600 mg/day is seldom indicated. [Semple 2007](#) advises that usual doses of 200 mg to 450 mg daily can be used, and that an increase in frequency of seizures occurs at doses greater than 600 mg/day. [Stahl 2006](#) suggests using 300 mg/day to 450 mg/day with a maximum of 900 mg/day, and that doses of more than 550 mg/day may require concomitant anticonvulsant medications to reduce the risk of seizures. Plasma levels may help guide dosing, with studies suggesting that maximal clinical efficacy may be achieved when plasma levels of clozapine are between 200 ng/ml and 400 ng/ml (typically associated with a dose of 300 mg/day to 400 mg/day ([Kronig 1995](#); [Simpson 1999](#))). However, it is important to note that the relationship between the dose of clozapine and the resulting serum level is weak ([Taylor 1995](#)). This could be a reason why there is wide variation of the clinically effective dose in different individuals. It is still unclear as to what dose of clozapine is most effective with the least side effects. It must be borne in mind as well that patient non-compliance can be as high as 50% under outpatient conditions and this could be due to drug-related side effects ([Gaebel 1997](#)), and lead to relapse. Clozapine produces severe adverse effects. Hence we will review the evidence for doses of clozapine that are both tolerable and effective in the management of schizophrenia, schizophreniform and schizoaffective disorders. This is one of a series of reviews on the effects of clozapine ([Table 1](#)).

### OBJECTIVES

To compare the efficacy and tolerability of clozapine at different doses and to identify the optimal dose of clozapine in the treatment of schizophrenia, schizophreniform and schizoaffective disorders.

### METHODS

#### Criteria for considering studies for this review

##### Types of studies

We included all relevant randomised controlled trials, reporting useable data, that compared different doses of clozapine, irrespective of blinding status and published language. Where people were given additional treatments along with clozapine, we included the trial only if the adjunct treatment was equal in both groups and only the clozapine doses were randomised. We included studies on treatment-resistant illnesses and took the opportunity to examine clozapine's effect on the course of the illness (for example acute, partial remission, remission, first episode). We excluded case series and non-randomised trials, and quasi-randomised trials where, for example, allocation is undertaken on alternate days of the week or by alphabetical order.

##### Types of participants

We included studies on people with schizophrenia, schizophreniform disorder and schizoaffective disorder diagnosed by any criteria. We decided to include schizophreniform and schizoaffective disorders as these conditions may be caused by similar disease processes and may require similar treatment approaches ([Carpenter 1994](#)).

##### Types of interventions

We compared the efficacy of different doses of clozapine in different arms in the same trial. We did not compare efficacy of clozapine to any other antipsychotic or to placebo or to any other medications. The intervention of interest was clozapine: oral formulation, any dose, comparison of different doses. We predefined the dosage categories as follows.

1. Very low dose clozapine: up to 149 mg/day.

2. Low-dose clozapine: 150 mg/day to 300 mg/day.
3. Standard-dose clozapine: 301 mg/day to 600 mg/day.
4. High-dose clozapine: 601 mg/day to 900 mg/day.
5. Very high dose clozapine: 901 mg/day and above.

### Types of outcome measures

We grouped outcomes into short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (more than 26 weeks).

#### Primary outcomes

##### 1. Global state

Clinically important response as defined by the individual studies (e.g. global impression "much improved" or 50% reduction on a rating scale).

#### Secondary outcomes

##### 1. Global state

- 1.1 Relapse (as defined by the individual studies).
- 1.2 Average endpoint global state score.
- 1.3 Average change in global state scores.
- 1.4 Needing additional medication.

##### 2. Mental state

- 2.1 Clinically important change in general mental state score.
- 2.2 Average endpoint general mental state score.
- 2.3 Average change in general mental state scores.
- 2.4 Clinically important change in specific symptoms (e.g. positive symptoms of schizophrenia, negative symptoms of schizophrenia).
- 2.5 Average endpoint specific symptom score.
- 2.6 Average change in specific symptom scores.
- 2.7 Healthy days.

##### 3. Death

- 3.1 Suicide.
- 3.2 Natural causes.

##### 4. Leaving the studies early

- 4.1 Any reason.
- 4.2 Specific reason (as described by individual studies; for example: adverse events, treatment inefficacy).

##### 5. Behaviour

- 5.1 Clinically important change in general behaviour.
- 5.2 Average endpoint general behaviour score.
- 5.3 Average change in general behaviour scores.
- 5.4 Clinically important change in specific aspects of behaviour.
- 5.5 Average endpoint specific aspects of behaviour.
- 5.6 Average change in specific aspects of behaviour.

##### 6. Functioning

- 6.1 Clinically important change in general functioning.
- 6.2 Average endpoint general functioning score.
- 6.3 Average change in general functioning scores.
- 6.4 No clinically important change in specific aspects of functioning, such as social or life skills.
- 6.5 Average endpoint specific aspects of functioning, such as social or life skills.
- 6.6 Average change in specific aspects of functioning, such as social or life skills.

##### 7. Cognitive functioning

- 7.1 Clinically important change in overall cognitive functioning.
- 7.2 Average endpoint overall cognitive functioning score.
- 7.3 Average change in overall cognitive functioning score.
- 7.4 Clinically important change in specific aspects of cognitive functioning.
- 7.5 Average endpoint specific aspects of cognitive functioning.
- 7.6 Average change in specific aspects of cognitive functioning.

##### 8. Quality of life

- 8.1 Clinically important change in general quality of life.
- 8.2 Average endpoint general quality of life score.
- 8.3 Average change in general quality of life score.
- 8.4 Clinically important change in specific aspects of quality of life.
- 8.5 Average endpoint specific aspects of quality of life.
- 8.6 Average change in specific aspects of quality of life.

##### 9. Adverse effects

- 9.1 Number of participants with at least one adverse effect.
- 9.2 Clinically important specific adverse effects (such as effects on white blood cell count, cardiac effects, movement disorders, hypersalivation, seizures, prolactin increase and metabolic side effects (such as weight gain, hyperlipidaemia and hyperglycaemia)).
- 9.3 Clinically important general adverse effects.
- 9.4 Average endpoint general adverse effect score.
- 9.5 Average change in general adverse effect score.
- 9.6 Average endpoint specific adverse effect score.
- 9.7 Average change in specific adverse effect score.
- 9.8 Use of any drugs for adverse effects.

##### 10. Satisfaction with treatment

- 10.1 Recipient of care not satisfied with treatment.
- 10.2 Recipient of care average satisfaction score.
- 10.3 Recipient of care average change in satisfaction score.
- 10.4 Carer not satisfied with treatment.
- 10.5 Carer average satisfaction score.
- 10.6 Carer average change in satisfaction score.

##### 11. Service use

- 11.1 Number of patients hospitalised.
- 11.2 Number of days hospitalised.
- 11.3 Time to hospitalisation.
- 11.4 Number of patients discharged or readmitted (as defined in individual trial).

##### 12. Economic outcomes

- 12.1 Direct costs.
- 12.2 Indirect costs.

##### 13. 'Summary of findings' table

We used the GRADE approach to interpret findings ([Schünemann 2011](#)); and GRADE Profiler ([GRADEpro GDT](#)) to import data from [Review Manager 5](#) (RevMan 5) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined and the sum of available data on all outcomes we rated as important to patient care and decision making. We selected the

following outcomes for inclusion in the [Summary of findings for the main comparison](#); [Summary of findings 2](#); [Summary of findings 3](#).

1. Global state: clinically important response, as defined by individual studies.
2. Mental state: clinically important response, as defined by individual studies.
3. Functioning: clinically important change in general functioning, including social or life skills, as defined by individual studies.
4. Adverse effect: clinically important adverse effect.
5. Service use: number of days hospitalised.
6. Service use: time to hospitalisation.
7. Quality of life: clinically important change in general quality of life.

## Search methods for identification of studies

### Electronic searches

#### *Cochrane Schizophrenia Group's Study-Based Register of Trials*

On 8 December 2016, the information specialist searched the register using the following search strategy:

Dosage - Clozapine in Intervention Field of STUDY

In a study-based register such as this, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics.

This register is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see [Group's Module](#)). There is no language, date, document type, or publication status limitations for inclusion of records in the register.

For previous searches, please see [Appendix 1](#).

### Searching other resources

#### 1. Reference searching

We searched the reference lists of each included paper, but failed to find any new studies.

#### 2. Personal contact

Where possible, we contacted the first author of trials or citations for missing information on unpublished data or trials. Where contact with the first author was not possible through the Cochrane Schizophrenia Group, we attempted to contact the other authors. At the time of writing, we have not received any of the missing data we requested, though one author indicated he will send the requested information at a future date. We have discussed this in detail under relevant Results sections.

## Data collection and analysis

### Selection of studies

One review author (SS) inspected citations from the searches, identified relevant abstracts, obtained full articles of all relevant abstracts, and classified studies as 'included', 'excluded', or 'with information missing'. We placed the last under 'pending

classification' and contacted the authors for further clarification. A second review author (BV) independently inspected a random 20% of citations to ensure reliability.

### Data extraction and management

#### 1.1 Data extraction

One review author (SS) extracted data from all included reports. To ensure reliability, a second review author (BV) independently extracted data from a random 25% sample of these reports. There was no disagreement. Had there been disagreement, we would have documented decisions and contacted authors of studies for clarification where necessary. We extracted data presented in graphs and figures only, whenever possible. We attempted to contact authors in order to obtain missing information or clarification whenever necessary.

#### 1.2 Forms

We extracted data onto standard forms.

### 2. Data management

#### 2.1 Scale-derived data

We included continuous data from rating scales only if (a) the psychometric properties of the measuring instrument had been described in a peer-reviewed journal ([Marshall 2000](#)), and (b) the measuring instrument had not been written or modified by one of the trialists for that particular trial. Ideally the measuring instrument should either be:

- (a) a self-report;
- (b) an instrument completed by an independent rater or relative (not the therapist);
- (c) a global assessment of an area of functioning and not sub-scores which are not, in themselves, validated or shown to be reliable. However there are exceptions: we included sub-scores from mental state scales measuring positive and negative symptoms of schizophrenia.

We realise that this is not often reported clearly and we note in [Description of studies](#) if this was the case or not.

#### 2.2 Endpoint versus change data

There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult-to-measure conditions such as schizophrenia. We primarily used endpoint data, and only used change data if the former were not available. We combined endpoint and change data in the analysis by the use throughout of mean differences (MD) rather than standardised mean differences ([Deeks 2011](#)).

#### 2.3 Skewed data

Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion: a) standard deviations and means are reported in the paper or obtainable from the authors;



b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (Altman 1996); c) if a scale started from a positive value (such as the PANSS which can have values from 30 to 210), the calculation described above was modified to take the scale starting point into account. In these cases skew is present if  $2SD > (S - S_{min})$ , where  $S$  is the mean score and  $S_{min}$  is the minimum score. Endpoint scores on scales often have a finite start and end point and the above rules can be applied. We did not come across skewed endpoint data in our review, but if we had then we would have entered skewed endpoint data from studies of fewer than 200 participants as other data within the [Data and analyses](#) section rather than into a statistical analysis. Skewed endpoint data would pose fewer problems when looking at means if the sample size is large, and we would have then entered these into syntheses.

When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not, and we would have entered skewed change data into statistical analysis.

#### 2.4 Common measure

To facilitate comparison between trials, where possible we tried to convert variables reported in different metrics (e.g. days spent in hospital as mean days per year or per week or per month) to a common metric (e.g. mean days per month).

#### 2.5 Conversion of continuous to binary

Where possible, we would have converted outcome measures to dichotomous data. This would have been done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the Positive and Negative Syndrome Scale (PANSS, Kay 1986), this could be considered as a clinically significant response (Leucht 2005a; Leucht 2005b). If data based on these thresholds had not been available, we would have used the primary cut-off presented by the original authors. Where data on clinical improvement was presented as 'very effective', 'effective' and 'no improvement', we grouped these to form the dichotomous outcome of 'effective'/'no improvement'.

#### 2.6 Direction of graphs

Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for lower dose of clozapine.

#### Assessment of risk of bias in included studies

One review author (SS) independently assessed risk of bias by using criteria described in the *Cochrane Handbook for Systematic Reviews of Interventions* to assess trial quality (Higgins 2011b). A second review author (BV) randomly checked 25% to ensure reliability. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. There was no disagreement. If there had been disagreement, we would have resolved it by further discussion. The level of risk of bias is noted in both the text of the review and in the 'Summary of findings' table.

#### Measures of treatment effect

##### 1. Binary data

For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios (Boissel 1999); and that odds ratios tend to be interpreted as RR by clinicians (Deeks 2000). The number needed to treat for an additional beneficial outcome/harmful outcome (NNTB/NNTH) statistic with its confidence intervals is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta-analyses and interpretation (Hutton 2009). For binary data presented in the 'Summary of findings' table/s, where possible we calculated illustrative comparative risks.

##### 2. Continuous data

We estimated mean difference (MD) between groups for continuous outcomes. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if very similar scales had been used, we would have presumed there was a small difference in measurement and would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments.

#### Unit of analysis issues

##### 1. Cluster trials

Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (Divine 1992), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (Bland 1997; Gulliford 1999).

There were no cluster trials included in our review. If there had been cluster studies, then where clustering was not accounted for in primary studies we would have presented data in a table, with a (\*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will contact first authors of studies to obtain intra-class correlation coefficients for their clustered data and adjust for this by using accepted methods (Gulliford 1999).

If clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non-cluster randomised study, but would have adjusted for the clustering effect. Statistical advice has been sought in the past: it was advised that binary data should be presented in a report and divided by a 'design effect'. This is calculated using the mean number of participants per cluster ( $m$ ) and the intra-class correlation coefficient (ICC): [Design effect =  $1 + (m - 1) * ICC$ ] (Donner 2002). If the ICC had not been reported we would have assumed it to be 0.1 (Ukoumunne 1999). If cluster studies had been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies might have been possible using the generic inverse variance technique.

## 2. Cross-over trials

We only used data from the first phase of cross-over studies. A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (Elbourne 2002). Because both these effects are very likely in severe mental illness, we decided to use data from the first phase of cross-over studies only. In our review, the Simpson 1999 trial was conducted in three phases of 16 weeks each, lasting for a total of 48 weeks with the last two phases being crossed over. For this trial we included the data from the first 16 weeks only (i.e. before cross-over occurred).

## 3. Studies with multiple treatment groups

There was no relevant additional treatment in any of the included trials. If a study had involved additional treatment arms, we would have presented the additional arms in comparisons only if relevant and would not have reproduced data from irrelevant arms. For binary data, we would simply have added these and combined within a two-by-two table. For continuous data, we would have combined the data following the formula in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011a). In cases where a study had two intervention arms which both fell within a single-dosage category defined in *Types of interventions* (for example, in Chen 2013 where both the 301 mg/day to 400 mg/day intervention and the 401 mg/day to 500 mg/day intervention fell within the 'standard' dose category), means and standard deviations were combined for continuous outcomes using methods described in section 7.7.3.8 of Higgins 2011a.

## Dealing with missing data

### 1. Overall loss of credibility

At some degree of loss of follow-up, data must lose credibility (Xia 2009). If more than 50% of data had been unaccounted for in any particular outcome, we had decided neither to reproduce these data nor to use them within our analyses. In this review, however, loss of data was never more than 50% for any outcome or in any arm. If the loss of data had been more than 50% but the total loss had been less than 50%, we would have marked such data with (\*) to indicate that the result might have been prone to bias.

### 2. Binary

Those who left the study early were all assumed to have the same outcome as those who completed, with the exception of the outcomes of death and adverse effects.

### 3. Continuous

#### 3.1 Attrition

Had attrition for a continuous outcome been between 0% and 50% and completer-only data had been reported, we would have reproduced these data.

#### 3.2 Standard deviations

In our review, there were few data whose standard deviations (SDs) were missing. We tried to obtain the missing values from the authors, but were unsuccessful. Where there are missing measures

of variance for continuous data, but an exact standard error (SE) and confidence intervals available for group means, and either P value or t value available for differences in mean, we can calculate them according to the rules described in the *Cochrane Handbook for Systematic reviews of Interventions* (Higgins 2011a): When only the standard error (SE) is reported, SDs are calculated by the formula  $SD = SE * \text{square root } (n)$ . The *Cochrane Handbook for Systematic reviews of Interventions* (Higgins 2011a) present detailed formulae for estimating SDs from P values, t or F values, confidence intervals, ranges or other statistics. If these formulae do not apply, we could calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (Furukawa 2006). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome and thus to lose information. We examined the validity of the imputations in a sensitivity analysis excluding imputed values. In our review we needed to exclude some outcome data as suggested by this last option.

### 3.3 Last observation carried forward

We anticipated that in some studies the method of last observation carried forward (LOCF) would have been reported. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (Leucht 2007). We found no cases where less than 50% of the LOCF data were available; if we had, we would have reproduced these data and indicated that they were based on LOCF assumptions.

## Assessment of heterogeneity

### 1. Clinical heterogeneity

We considered all included studies initially, without seeing comparison data to judge clinical heterogeneity. We inspected all studies for clearly outlying people or situations which we had not predicted would arise, but we did not come across any such outlying conditions.

### 2. Methodological heterogeneity

We considered all included studies initially without seeing comparison data to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise, but we did not come across any such outlying methods.

### 3. Statistical heterogeneity

#### 3.1 Visual inspection

We visually inspected the graphs to investigate the possibility of statistical heterogeneity.

#### 3.2 Employing the I<sup>2</sup> statistic

We investigated heterogeneity between studies by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> P value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of I<sup>2</sup> depends on (i) magnitude and direction of effects, and (ii) strength of evidence for heterogeneity (e.g. P value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). I<sup>2</sup> estimates greater than or equal to 50% and accompanied by a statistically significant Chi<sup>2</sup> statistic are interpreted as evidence of substantial levels of heterogeneity (Deeks 2011). If substantial levels of heterogeneity

had been found in the primary outcome, we would have explored reasons for heterogeneity ([Subgroup analysis and investigation of heterogeneity](#)).

## Assessment of reporting biases

### 1. Protocol versus full study

We attempted to locate protocols of the included randomised trials but were unsuccessful. We therefore compared the outcomes listed in the Methods section of the trial report with those actually reported in the results.

### 2. Funnel plot

Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results ([Egger 1997](#)). These are described in Chapter 10 of the *Cochrane Handbook for Systematic Reviews of Interventions* ([Sterne 2011](#)). We are aware that funnel plots may be useful in investigating reporting biases but have limited power to detect small-study effects. We did not use funnel plots as there were only three randomised controlled studies included in this review.

## Data synthesis

We understand that there is no closed argument in favour of either a fixed-effect or a random-effects model. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random-effects model: it adds weight to small studies, which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose a random-effects model for all analyses. The reader is, however, able to choose to inspect the data using the fixed-effect model by opening this review in RevMan 5 format and selecting to view by "fixed effect" model under the properties section of each graph.

## Subgroup analysis and investigation of heterogeneity

### 1. Subgroup analyses

We had planned to report data on subgroups of participants (for example, those who received additional medications or had additional diagnoses), but we did not encounter such subgroups.

#### 1.1 Clinical state, stage or problem

This review provides an overview of the effects of clozapine for people with schizophrenia, schizophreniform and schizoaffective disorder. Our aim was also to report data on subgroups of people in the same clinical state, stage and with similar problems (for example patients in agitated state, partial remission, remission or first episode), but we did not come across any such subgroups.

### 2. Investigation of heterogeneity

We report if inconsistency was high. First, we investigated whether data were entered correctly. Secondly, if the data were correct, we visually inspected the graphs and successively removed outlying studies to see if heterogeneity was restored. For this review we decided that we would present the data if this occurred in no more than 10% of the total weighting of the summary findings. If not, we would not pool data but would only discuss the issues. If

unanticipated clinical or methodological heterogeneity had been obvious, we would have stated the hypotheses regarding these for future reviews or versions of this review and would not have undertaken analyses relating to these.

## Sensitivity analysis

### 1. Implication of randomisation

We would have included in a sensitivity analysis primary outcomes data from studies where randomisation was implied but was not clearly described, but we did not come across such studies. If there had been no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we would have employed all data from these studies.

### 2. Assumptions for lost binary data

Where assumptions were made regarding participants lost to follow-up (see [Dealing with missing data](#)) we would have compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there had been a substantial difference, we would have reported the results and discussed them but would have continued to employ our assumption. Where assumptions were made regarding missing SDs data (see [Dealing with missing data](#)), we would have compared the findings on primary outcomes when we used our assumption compared with completer data only. We would have undertaken a sensitivity analysis testing as to how prone results would have been to change with completer data only compared to the imputed data using the above assumption. If there would have been a substantial difference, we would have reported these results and discussed them but would have continued to employ our assumption. We did not have to make such assumptions in our review.

### 3. Risk of bias

We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains — randomisation, allocation concealment, blinding and outcome reporting and other bias — for the meta-analyses of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis.

### 4. Imputed values

We did not include any cluster trials. If any had been included, we would have undertaken sensitivity analysis to assess the effects of including data from trials where we had used imputed values for ICCs in calculating the design effect. If substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses had been noted, we would not have pooled data, but would have presented them separately.

### 5. Fixed-effect and random-effects

We synthesised all data using a random-effects model.

---

## RESULTS


### Description of studies

For substantive description of studies please also see [Characteristics of included studies](#), [Characteristics of excluded studies](#) and Characteristics of ongoing studies.

### Results of the search

The search strategy yielded 122 citations. One was a duplicate. We closely inspected 23 full-text reports; and after excluding 18 full-text reports, we included five studies in the review. A random 20% of the citations were independently reviewed by one review author (BV) to increase reliability. Details of the search results are illustrated in the PRISMA table ([Figure 2](#)).

**Figure 2. Study flow diagram.**



## Included studies

We included five studies with a total of 452 participants.

### 1. Study length

[Chen 1998](#) and [Chen 2013](#) were short-term trials lasting six weeks. [Sheng 1990](#) and [Liu 2005](#) were also short term (12 weeks). The [Simpson 1999](#) trial was originally conducted in three phases of 16 weeks each, lasting for a total of 48 weeks. However, after the first 16 weeks, the non-responders in the trial were crossed over to other arms and hence they were not randomised anymore after the initial 16 weeks. So, as per protocol, we included the results of only the first 16 weeks (medium term: 13 to 26 weeks) from these citations. There were no long-term studies (> 26 weeks).

### 2. Design

All included studies were randomised controlled trials. [Chen 1998](#) is a randomised controlled trial comparing the efficacy of clozapine at doses of 200 mg and 500 mg; details of blinding status and of any sponsorship are unclear. [Liu 2005](#) is a randomised controlled trial comparing clozapine at doses of less than 150 mg/day, 150 mg/day to 300 mg/day and more than 300 mg/day, in which participants were allocated using a random number table; details of blinding status and of any sponsorship are unclear. [Chen 2013](#) is a randomised trial comparing doses of 200 mg/day to 300 mg/day, 301 mg/day to 400 mg/day and 401 mg/day to 500 mg/day. [Sheng 1990](#) is a randomised trial comparing doses of 300 mg/day and 600 mg/day. [Simpson 1999](#) is an implied randomised controlled trial comparing the efficacy of clozapine at different doses of 100 mg/day, 300 mg/day and 600 mg/day in 50 patients. The trial was sponsored by Novartis Pharmaceuticals and conducted between 1992 and 1995; the participants stayed in the research centre for four weeks for adaptation (naturalistic baseline with no modification in their treatment regimen) and underwent a four-week haloperidol treatment followed by a one-week wash out before the first phase of clozapine treatment.

### 3. Participants

A total of 452 participants were included in the five trials. [Chen 1998](#) conducted their study on a total of 176 male and female patients, aged between 17 and 55 years, suffering from schizophrenia and with illness duration of 8 ( $\pm$  11 months) on average. [Liu 2005](#) included 87 male patients aged between 18 and 45 years and used CCMD-3 to diagnose patients suffering from schizophrenia. [Chen 2013](#) and [Sheng 1990](#) randomised 90 and 51 patients with schizophrenia, respectively. [Simpson 1999](#) was conducted on a total of 22 males and 28 females with a mean age of 44.8 years (range 35 to 54) suffering from schizophrenia, treatment refractory or schizoaffective disorder, diagnosed by DSM-III-R criteria. Mean illness duration was 25.1 years (range 1 to 38 years) and the median number of psychiatric hospitalisations was five (range 1 to 25). Patients had not shown a satisfactory clinical response to treatment with at least three neuroleptic drugs (each given for at least six weeks in doses equivalent to 1000 mg/day of chlorpromazine).

### 4. Settings

[Simpson 1999](#) used a research ward inpatient setting in a State hospital in the USA. [Liu 2005](#) was conducted in an inpatient setting in a medical college. The settings for [Chen 1998](#), [Chen 2013](#) and [Sheng 1990](#) were unclear.

## 5. Interventions

We classified interventions into five groups according to clozapine dosage. [Liu 2005](#) administered clozapine at less than 150 mg/day (very low dose), at 150 mg/day to 300 mg/day (low dose) and at more than 300 mg/day (standard dose). [Simpson 1999](#) administered clozapine at 100 mg/day (very low dose), 300 mg/day (low dose) and 600 mg/day (standard dose). [Chen 1998](#) administered clozapine at 200 mg/day (low dose) and at 500 mg/day (standard dose). [Chen 2013](#) administered doses of 200 mg/day to 300 mg/day, 301 mg/day to 400 mg/day and 401 mg/day to 500 mg/day. [Sheng 1990](#) administered doses of 300 mg/day and 600 mg/day. No trial administered clozapine at more than 601 mg/day (high dose) or more than 901 mg/day (very high dose).

## 6. Outcomes

### 6.1 Rating scales

Details of the scales that provided usable data are shown below. Reasons for exclusions of data and/or scales are given under 'Outcomes' in the [Characteristics of included studies](#) table.

#### 6.1.1 Mental state

##### 6.1.1.1 Brief Psychiatric Rating Scale – BPRS ([Overall 1962](#))

The BPRS is an 18-item scale measuring positive symptoms, general psychopathology and affective symptoms. High scores indicate more severe symptoms. The original scale has 16 items that are rated in interview format using Likert scale ratings from 1 ('absent') to 7 ('very severe') with scores ranging from 0 to 112. A revised 18-item scale is commonly used with scores ranging from 0 to 126. The BPRS-A is an anchored version of the BPRS. It describes expected symptoms and problems for each of the seven rating options for each item. As such, it is thought that the BPRS-A anchor points provide an increased level of standardisation, leading to an improvement in rater reliability ([Woerner 1988](#)). The BPRS-A and its subscales have been validated ([Lachar 2001](#)). [Chen 1998](#) and [Simpson 1999](#) reported data on the BPRS-A.

#### 6.1.2 Adverse events

##### 6.1.2.1 Treatment-Emergent Signs and Symptoms - TESS ([NIMH 1985](#))

This checklist assesses a variety of characteristics for each adverse event, including severity, relationship to the drug, temporal characteristics (timing after a dose, duration and pattern during the day), contributing factors, course, and action taken to counteract the effect. Symptoms can be listed a priori or can be recorded as observed by the investigator. A low score indicates low levels of adverse effects. [Chen 1998](#) and [Chen 2013](#) reported data on this outcome.

## Excluded studies

Of the 122 references identified using the search strategy, one was a duplicate. We closely inspected 28 reports and excluded 23. [Liu 2005a](#) and [Tang 2000](#) were not randomised trials. All data were missing in [de Leon 1995a](#) and [de Leon 2004](#) and we contacted the author who confirmed that no further data were available. [de Leon 2003](#) was excluded as the data on serum antimuscarinic activity was missing at 16 weeks before the cross-over point. [Potkin 1993](#) and [Potkin 1994](#) also had all data missing from the reports and no data were useable; we contacted the author regarding the missing

data but no response has been received at the time of writing. We excluded [Han 2001](#) as different doses of sulpiride were prescribed in the clozapine arms. [VanderZwaag 1996](#) and [VanderZwaag 1997](#) compared the effectiveness of different serum clozapine levels, but not the effects of different doses of clozapine. [Nair 1998](#) and [Nair 1999](#) were excluded because the authors compared those with and without probable tardive dyskinesia in subgroups of 23 and 33 participants respectively from the [Simpson 1999](#) trial, but provided no additional data relevant to this review.

**Studies awaiting classification**

[Abraham 1997](#) is a report of a trial conducted from 1992 to 1995, reported in detail in [Simpson 1999](#) where it is mentioned that global state was measured using the Clinical Global Impression (CGI) and these data would be discussed in [Abraham 1997](#). However, [Abraham 1997](#) only retrospectively analysed the data on responders and non-responders; four participants responded, but

it was unclear from the report which groups they belonged to and the CGI data for the dosage groups were also missing. We contacted the main trialist who indicated he would provide the missing data, but this has not been received at the time of writing. If we receive this subsequently, we will include it in an update of this review.


**Ongoing studies**

We did not identify any ongoing studies.

**Risk of bias in included studies**

None of the studies explicitly described the allocation process fully. Some of the studies were selective in presenting their data on outcomes. Some of the outcomes in the trials could not be used and we have not received missing data we requested from the authors of the trials. [Simpson 1999](#) was a trial sponsored by a clozapine drug company. See [Figure 3](#), [Figure 4](#).

**Figure 3. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.**



**Figure 4. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.**

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Chen 1998	?	?	-	-	+	+	?
Chen 2013	?	?	-	-	+	+	?
Liu 2005	+	?	-	-	+	+	+
Sheng 1990	?	?	?	?	+	-	?
Simpson 1999	-	?	?	+	-	-	-

**Allocation**

All five studies were described as randomised. Allocation in [Liu 2005](#) was via a random number generator. [Simpson 1999](#), [Sheng 1990](#), [Chen 2013](#) and [Chen 1998](#) did not describe the methods used to generate the allocation sequence. None of the studies reported on how the results of allocation were concealed.

**Blinding**

[Simpson 1999](#) was described as a double-blind trial with assessors blinded and all patients receiving the same number of identical capsules every time, although the authors appear not to have tested the success of blinding for participants or evaluators.

This may increase the risk of observer bias with potential for overestimation of positive effects and underestimation of negative ones. [Chen 1998](#) and [Liu 2005](#) did not report if their trials were blinded. [Chen 2013](#) and [Sheng 1990](#) did not report how blinding took place. Blinding may be less important for objective outcomes such as death, but the studies included here reported only subjective outcomes.

**Incomplete outcome data**

[Chen 1998](#), [Chen 2013](#) and [Sheng 1990](#) appear to have had no loss to follow up. [Liu 2005](#) reported on three participants who left the study early with clear reasons for doing so. [Simpson 1999](#) reported the number leaving the study early and explicitly described that



their last observations were carried forward; however, data on the scale for the Assessment of Negative Symptoms (SANS) were not reported. de Leon 2007 reported data on patients who completed the Simpson 1999 trial. However the number of patients on whom measures were reported differed slightly from week to week, and it is unclear why the number of patients on whom measurements were reported at each week differed, who had missed their measurements and why the measurements were not taken.

### Selective reporting

Simpson 1999 did not report on SANS. Sheng 1990 did not report BPRS or TESS scores. Simpson 1999 reported responders' and non-responders' data only at 48 weeks, which is after the cross-over point at 16 weeks. No data is reported before the cross-over.

### Effects of interventions

See: [Summary of findings for the main comparison Clozapine: very low dose \(up to 149 mg/day\) versus low dose \(150 mg/day to 300 mg/day\) for schizophrenia](#); [Summary of findings 2 Clozapine: very low dose \(up to 149 mg/day\) versus standard dose \(301 mg/day to 600 mg/day\) for schizophrenia](#); [Summary of findings 3 Clozapine: low dose \(150 mg/day to 300 mg/day\) versus standard dose \(301 mg/day to 600 mg/day\) for schizophrenia](#)

In the text below, data from Simpson 1999 have been adjusted in accordance with the published corrections (Simpson 2001). Specifically, the standard errors for BPRS-A endpoint scores which were originally reported by the authors as if they were standard deviations have been converted to standard deviations.

#### Comparison 1: clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day)

##### 1.1 Mental state: average endpoint scores (BPRS-A, high = poor) – medium term

Simpson 1999 found no significant difference in endpoint mental state scores at 16 weeks measured using the BPRS-A (n = 31, MD 3.55, 95% CI -4.50 to 11.60; [Analysis 1.1](#)).

##### 1.2 Adverse effects: 1a. weight - BMI (kg/m<sup>2</sup>) – short term

Liu 2005 found no significant difference in BMI at the end of six weeks in the very low dose group compared to the low dose group (n = 59, MD -0.10, 95% CI -0.95 to 0.75; [Analysis 1.2](#)).

##### 1.3 Adverse effects: 1b. weight gain (kg; average)

Simpson 1999 (reported in de Leon 2007) found no significant difference between the groups in weight gain at week 12 (n = 27, 1 RCT, MD -1.10, 95% CI -3.93 to 1.73; [Analysis 1.3](#)). There was similarly no significant difference between the groups in weight gain at 16 weeks (n = 28, 1 RCT, MD -1.30, 95% CI -4.86 to 2.26; [Analysis 1.3](#)).

##### 1.4 Adverse effects: 1c. weight – body weight at endpoint (kg; average) – short term

Liu 2005 found no significant difference in body weight between the groups at the end of six weeks (n = 59, 1 RCT, MD 0.00, 95% CI -3.92 to 3.92; [Analysis 1.4](#)).

One study, Liu 2005, reported on two other adverse effects.

##### 1.5 Adverse effects: 2a. metabolic – blood glucose – before and after meal

No difference between the groups were found before a meal (n = 59, 1 RCT, MD -0.40, 95% CI -1.06 to 0.26), one hour after meal (n = 59, 1 RCT, MD -0.70, 95% CI -2.01 to 0.61), two hours after meal (n = 59, 1 RCT, MD 0.30, 95% CI -0.98 to 1.58) and three hours after meal (n = 59, 1 RCT, MD -0.70, 95% CI -1.59 to 0.19). There was no significant difference in the overall analysis (n = 59, 1 RCT, MD -0.43, 95% CI -0.89 to 0.03; [Analysis 1.5](#)).

##### 1.6 Adverse effects: 2b. metabolic - lipid profile - short term

Participants on low-dose clozapine had significantly lower serum triglycerides than those on a very low dose (n = 59, 1 RCT, MD 1.00, 95% CI 0.51 to 1.49). Otherwise there was no significant difference between the groups in terms of serum total cholesterol (n = 59, 1 RCT, MD 0.50, 95% CI -0.12 to 1.12), high density lipoprotein (HDL) (n = 59, 1 RCT, MD 0.04, 95% CI -0.14 to 0.22), low density lipoprotein (LDL) (n = 59, 1 RCT, MD 0.10, 95% CI -0.36 to 0.56), Apo-A1 (n = 59, 1 RCT, MD 0.05, 95% CI -0.10 to 0.20) and Apo-B (n = 59, 1 RCT, MD 0.13, 95% CI -0.16 to 0.42). All [Analysis 1.6](#).

##### 1.7 Leaving the study early

Simpson 1999 found no significant difference in numbers leaving the study early between the groups in the medium term for any reason (n = 31, 1 RCT, RR 6.00, 95% CI 0.31 to 115.56; [Analysis 1.7](#)). Liu 2005 reported no significant difference between the groups in the short term due to specific side effects (n = 60, 1 RCT, RR 0.33, 95% CI 0.01 to 7.87; [Analysis 1.7](#)). The overall analysis showed no significant difference in the numbers leaving the study early between the very low dose and the low-dose groups in the short and medium term (n = 91, 2 RCTs, RR 1.50, 95% CI 0.09 to 25.41; [Analysis 1.7](#)).

##### Missing outcomes

For this comparison, no studies reported on global state, death, behaviour, functioning, quality of life, satisfaction with treatment, service use and economic costs.

#### Comparison 2: clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day)

##### 2.1 Mental state: average endpoint scores (BPRS-A, high = poor) – medium term

Simpson 1999 found no significant difference in mean endpoint BPRS-A scores at 16 weeks (n = 31, 1 RCT, MD 6.67, 95% CI -2.09 to 15.43; [Analysis 2.1](#)).

##### 2.2 Adverse effects: 1a. weight – BMI (in kg/m<sup>2</sup>) – short term

Liu 2005 found no significant difference in body mass index (BMI) at the end of six weeks in the very low dose group compared to the standard-dose group (n = 58, 1 RCT, MD 0.10, 95% CI -0.76 to 0.96; [Analysis 2.2](#)).

##### 2.3 Adverse effects: 1b. weight – weight gain (kg; average)

Simpson 1999 (reported by de Leon 2007) found significantly lower weight gain in the very low dose group at 12 weeks (n = 27, 1 RCT, MD -2.70, 95% CI -5.38 to -0.02), although no significant difference between the groups at 16 weeks (n = 28, 1 RCT, MD -3.10, 95% CI -6.73 to 0.53; [Analysis 2.3](#)).

### 2.4 Adverse effects: 1c. body weight at endpoint – short term (kg; average)

Liu 2005 found no significant difference in body weight between the groups at six weeks (n = 58, 1 RCT, MD 1.00, 95% CI –2.66 to 4.66; Analysis 2.4).

### 2.5 Adverse effects: 2a. metabolic – blood glucose – short term

Liu 2005 found that glucose level one hour after a meal was significantly less in the very low dose group (n = 58, 1 RCT, MD –1.60, 95% CI –2.90 to –0.30). There was no significant difference between the groups before meal (n = 58, 1 RCT, MD –0.10, 95% CI –0.68 to 0.48), two hours after meal (n = 58, 1 RCT, MD –0.60, 95% CI –1.89 to 0.69) or three hours after meal (n = 58, 1 RCT, MD –0.30, 95% CI –1.55 to 0.95). There was no significant difference in the overall analysis between the groups (n = 58, 1 RCT, MD –0.49, 95% CI –1.12 to 0.13). All Analysis 2.5.

### 2.6 Adverse effects: 2b. lipid profile – short term

Liu 2005 found that standard dose was associated with significantly lower serum levels of total cholesterol (n = 58, 1 RCT, MD 1.00, 95% CI 0.20 to 1.80), triglycerides (n = 58, 1 RCT, MD 1.30, 95% CI 0.81 to 1.79) and Apo-B (n = 58, 1 RCT, MD 0.23, 95% CI 0.01 to 0.45). No significant difference was found between the groups in high density lipoprotein (HDL) (n = 58, 1 RCT, MD 0.10, 95% CI –0.13 to 0.33), low density lipoprotein (LDL) (n = 58, 1 RCT, MD 0.00, 95% CI –0.39 to 0.39) or Apo-A1 levels (n = 58, 1 RCT, MD 0.04, 95% CI –0.10 to 0.18). All Analysis 2.6.

### 2.7 Leaving the study early

Simpson 1999 found no significant difference in numbers leaving the study early for any reason between the groups in the medium term (n = 31, 1 RCT, RR 1.21, 95% CI 0.20 to 7.55). Liu 2005 reported no significant difference between the groups in numbers leaving the study early due to specific physical side effects in the short term (n = 60, 1 RCT, RR 0.20, 95% CI 0.01 to 4.00). The overall analysis showed no significant difference between the groups (n = 91, 2 RCTs, RR 0.73, 95% CI 0.14 to 3.72; Analysis 2.7).

### Missing outcomes

For this comparison, no studies reported on global state, death, behaviour, functioning, quality of life, satisfaction with treatment, service use and economic costs.

## Comparison 3: clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day)

### 3.1 Mental state: 1a. clinically important response (BPRS score > 30% change)

Chen 1998 found no significant difference in curative rate between the groups (n = 176, 1 RCT, RR 0.93, 95% CI 0.78 to 1.10; Analysis 3.1).

### 3.2 Mental state: 1b. average endpoint score (BPRS-A total, high = poor)

Chen 1998 reported no significant difference between the groups for total scores at week 6 (n = 176, 1 RCT, MD 1.70, 95% CI –1.26 to 4.66; Analysis 3.2). Simpson 1999 reported no significant difference between the groups for total scores at 16 weeks (n = 34, 1 RCT, MD 3.12, 95% CI –4.20 to 10.44; Analysis 3.2).

### 3.3 Mental state: 1c. average endpoint score (BPRS-A, subscores, high = poor)

#### 3.3.1 Anxiety

Chen 1998 found no significant difference between the groups at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI –0.09 to 0.09; Analysis 3.3).

#### 3.3.2 Blunted Affect

Chen 1998 found no significant difference between the groups at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI –0.18 to 0.18; Analysis 3.3).

#### 3.3.3 Conceptual Disorganisation

Chen 1998 found no significant difference between the groups at week 6 (n = 176, 1 RCT, MD 0.20, 95% CI –0.02 to 0.42, Analysis 3.2.5).

#### 3.3.4 Excitement

Chen 1998 found no significant difference between the groups at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI –0.10 to 0.10; Analysis 3.3).

#### 3.3.5 Uncooperativeness

Chen 1998 found no significant difference between the groups at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI –0.21 to 0.21; Analysis 3.3).

### 3.4 Mental state: 1d. clinical improvement (clinician assessed)

There was no significant difference between groups at 12 weeks (Chen 1998; Chen 2013) (n = 141, 2 RCTs, RR 0.76, 95% CI 0.36 to 1.61; Analysis 3.4).

### 3.5 Adverse effects: 1a. weight – BMI (in kg/m<sup>2</sup>) – short term

Liu 2005 found no significant difference in body mass index at the end of six weeks in the low dose group compared to the standard dose group (n = 57, 1 RCT, MD 0.20, 95% CI –0.84 to 1.24; Analysis 3.5).

### 3.6 Adverse effects: 1b. weight – weight gain (kg; average)

Simpson 1999 (reported in de Leon 2007) found no significant difference in weight gain between the groups at week 12 (n = 30, 1 RCT, MD –1.60, 95% CI –4.47 to 1.27) or week 16 (n = 30, MD –1.80, 95% CI –5.38 to 1.78; Analysis 3.6).

### 3.7 Adverse effects: 1c. body weight at endpoint (kg; average) – short term

Liu 2005 found no significant difference in body weight between the groups in the short term (n = 57, 1 RCT, MD 1.00, 95% CI –3.42 to 5.42; Analysis 3.5.4).

### 3.8 Adverse effects: 2a. metabolic – blood glucose – short term

Liu 2005 found no significant difference in glucose levels between the groups before meal (n = 57, 1 RCT, MD 0.30, 95% CI –0.23 to 0.83; Analysis 3.8), one hour after meal (n = 57, 1 RCT, MD –0.90, 95% CI –2.33 to 0.53; Analysis 3.8), two hours after meal (n = 57, 1 RCT, MD –0.90, 95% CI –2.14 to 0.34; Analysis 3.8), three hours after meal (n = 57, 1 RCT, MD 0.40, 95% CI –0.84 to 1.64; Analysis 3.8). There was no difference between the groups in the overall analysis (1 RCT, MD –0.12, 95% CI –0.79 to 0.56; Analysis 3.8).

### 3.9 Adverse effects: 2b. metabolic – lipid profile – short term

Liu 2005 found no significant difference between the groups in serum total cholesterol (n = 57, 1 RCT, MD 0.50, 95% CI –0.29 to 1.29; Analysis 3.9), triglycerides (n = 57, 1 RCT, MD 0.30, 95% CI –0.12 to

0.72; [Analysis 3.9](#)), high density lipoprotein (HDL) (n = 57, 1 RCT, MD 0.06, 95% CI -0.16 to 0.28; [Analysis 3.9](#)), low density lipoprotein (LDL) (n = 57, 1 RCT, MD -0.10, 95% CI -0.50 to 0.30; [Analysis 3.9](#)), Apo A-1 (n = 57, 1 RCT, MD -0.01, 95% C -0.14 to 0.12; [Analysis 3.9](#)) and Apo-B levels (n = 57, 1 RCT, MD 0.10, 95% CI -0.14 to 0.34; [Analysis 3.9](#)).

### 3.10 Adverse effects: 3. various effects – short term

[Chen 1998](#) found a significantly greater incidence in the standard compared to the low dose group for lethargy (n = 176, RR 0.77, 95% CI 0.60 to 0.97; [Analysis 3.10](#)), hypersalivation (n = 176, RR 0.70, 95% CI 0.57 to 0.84; [Analysis 3.10](#)), dizziness (n = 176, RR 0.56, 95% CI 0.39 to 0.81; [Analysis 3.10](#)) and tachycardia (n = 176, RR 0.57, 95% CI 0.45 to 0.71; [Analysis 3.10](#)).

### 3.11 Adverse effects: 4. average endpoint score (TESS, high = poor) – short term

Meta-analysis of two studies, [Chen 1998](#) and [Chen 2013](#), found total TESS scores were significantly lower in the low-dose group compared to standard dose (n = 124, 2 RCTs, MD -3.99, 95% CI -5.75 to -2.24; [Analysis 3.11](#)). [Chen 1998](#) found that TESS scores were significantly lower in the low-dose group compared to standard dose on sub scores for behavioural toxicity (n = 176, 1 RCT, MD -1.00, 95% CI -1.51 to -0.49; [Analysis 3.11](#)), vegetative nervous system (n = 176, 1 RCT, MD -0.90, 95% CI -1.61 to -0.19; [Analysis 3.11](#)) and cardiovascular system (n = 176, 1 RCT, MD -0.60, 95% CI -0.98 to -0.22; [Analysis 3.11](#)).

### 3.12 Leaving the study early

For this comparison, no participant left the study early in [Chen 1998](#). [Simpson 1999](#) found no significant difference in numbers leaving the study early for any reason between the groups in the medium term (n = 34, 1 RCT, RR 0.20, 95% CI 0.01 to 3.88; [Analysis 3.12](#)). [Liu 2005](#) found no significant difference in numbers leaving the study early between the groups in the short term due to specific side effects (n = 60, 1 RCT, RR 0.50, 95% CI 0.05 to 5.22; [Analysis 3.12](#)). There was no difference between the groups in the overall analysis (n = 47, 2 RCTs, RR 0.35, 95% CI 0.06 to 2.21; [Analysis 3.12](#)).

### Missing outcomes

For this comparison, no studies reported on global state, death, behaviour, functioning, quality of life, satisfaction with treatment, service use and economic costs.

## DISCUSSION

### Summary of main results

We included five studies with data from 452 participants suffering from schizophrenia and schizoaffective disorders diagnosed by any criteria. We categorised doses of clozapine into five categories: very low dose clozapine: up to 149 mg/day; low-dose clozapine: 150 mg/day to 300 mg/day; standard-dose clozapine: 301 mg/day to 600 mg/day; high-dose clozapine: 601 mg/day to 900 mg/day; and very high dose clozapine: 901 mg/day and above. [Simpson 1999](#) compared the effects of clozapine at doses of 100 mg/day (very low), 300 mg/day (low dose) and 600 mg/day (standard dose) over both short term (up to 12 weeks) and medium term (16 weeks). [Chen 2013](#) compared doses of 200 mg/day to 300 mg/day, 301 mg/day to 400 mg/day, and 401 mg/day to 500 mg/day over 12 weeks. [Sheng 1990](#) compared doses of 300 mg/day and 600 mg/day over

12 weeks. [Liu 2005](#) compared effects of three different doses of clozapine: less than 150 mg/day (very low dose); 150 mg/day to 300 mg/day (low dose); and more than 300 mg/day (standard) over short term.

[Liu 2005](#) reported over six weeks on outcomes including leaving the study early, body weight, body mass index (BMI), lipid profile and blood glucose levels measured before meals, and one hour, two hours and three hours after meals. [Chen 2013](#) reported on mental state as clinical improvement (clinician assessed), and on TESS scale scores. Outcomes reported by [Sheng 1990](#) were mental state as clinical improvement (clinician assessed), but the authors did not report BPRS scores or TESS scale scores.

[Chen 1998](#) compared clozapine at doses of 200 mg/day (low dose) and 500 mg/day (standard dose) in short-term and reported data over six weeks on outcomes including global state on clinically important response as defined by individual studies (curative rate: BPRS score < 30% change = no improvement), mental state on the Brief Psychiatric Rating scale-Anchored (BPRS-A) and subscores of this scale, and adverse reaction using the TESS scale and the incidence of lethargy, hypersalivation, dizziness, and tachycardia.

[Simpson 1999](#) reported on leaving the study early, BPRS-A total scores. Though their report stated that they measured CGI and SANS, these data were not reported in the paper. Data on end body weight, weight gain and BMI over shorter term and medium term were reported in [de Leon 2007](#). Data on BMI could not be used as it was not presented according to doses. We also could not use data on “clinically important response as defined by individual studies” as the details of responders were presented only at 48 weeks and not at 16 weeks (before cross-over). In addition, it is reported that four people responded at end of 16 weeks, but it is unclear which dosage group these four patients belonged to. [Simpson 1999](#) stated that data on CGI would be discussed in [Abraham 1997](#), but we found that was not the case. We contacted the author for data on CGI, SANS, data on responders at 16 weeks and the details on which arm the four responders belonged to but we have not received the data at the time of writing.

There were no studies comparing high dose or very high dose of clozapine and none of the reports identified presented outcomes in the longer term.

### 1 Comparison: clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day)

#### Short term

We found no evidence relating to clinical response. In terms of adverse effects, in one RCT of 59 participants there was no difference between the groups in BMI at endpoint with the very low dose group only 0.1 lower (0.95 lower to 0.75 higher) ([Liu 2005](#)). On other outcomes, the same study found low-dose clozapine associated with lower serum triglycerides compared to very low dose, but no differences between the groups in other elements of the lipid profile, in blood glucose levels, in body weight at endpoint or in leaving the study early.

#### Medium term

We found no evidence relating to clinical response. In one small RCT of 31 participants ([Simpson 1999](#)), there was no difference between the groups in average BPRS-A scores and no difference on change

in mental state score. On other outcomes, no difference was found between the groups in terms of weight gain or number leaving the study early (Simpson 1999).

## **2 Comparison: clozapine: very low (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day)**

### **Short term**

We found no evidence relating to clinical response in the short term. In terms of adverse effects, in one RCT of 58 participants there was no difference between the groups in BMI at endpoint with the very low dose group only 0.1 higher (0.76 lower to 0.96 higher) (Liu 2005). There was no difference in body weight at endpoint in the same study, although the very low dose group had less weight gain than the standard-dose group at six and 12 weeks. On other outcomes, we found evidence in one study that the very low dose group had lower glucose levels one hour post meal compared to the standard-dose group, but otherwise there was no difference between the groups in blood glucose measurements (Liu 2005); and no difference between the groups in numbers leaving the study early. In the same study, at six weeks standard dose was associated with lower serum triglycerides, serum total cholesterol and Apo-B, but otherwise there was no difference between the groups in terms of lipid profile (Liu 2005). These results should be interpreted with caution as this trial was conducted only for six weeks with a small number of participants.

### **Medium term**

We found no evidence relating to clinical response in the medium term. On other outcomes, no differences between the groups were found in the medium term for weight gain or numbers leaving the study early (Simpson 1999).

## **3. Comparison: clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day)**

### **Short term**

We found no evidence relating to clinical response or to clinically significant response in global state in the short term. In one RCT of 57 participants there was no difference between the groups in BMI at endpoint with the low-dose group only 0.2 higher (0.84 lower to 1.24 higher) (Liu 2005). On other outcomes, there was no difference between the groups on body weight at endpoint, lipid profile or blood glucose measurements. Side effects measured by TESS were less in the low-dose group in two studies (Chen 1998; Chen 2013), and the incidence of lethargy, hypersalivation, dizziness and tachycardia were also less in the low-dose group in one study (Chen 1998).

### **Medium term**

We found no evidence from one RCT of 34 participants that mental state at endpoint, numbers leaving the study early or weight gain differed between the groups (Simpson 1999).

## **4. Missing outcomes**

There was no information available on other important outcomes such as clinically significant response in social or life skills, relapse, prolactin increase, service use, satisfaction with care or quality of life.

## **5. Summary**

We identified just three randomised controlled trials that met our inclusion criteria. We looked at a range of different doses including very low (up to 149 mg/day), low (150 mg/day to 300 mg/day), standard (301 mg/day to 600 mg/day), high (601 mg/day to 900 mg/day) and very high (901 mg/day and above). All trials identified compared very low dose, low dose and standard dose only. No trials were identified comparing high dose or very high dose to standard dose. Two studies were only of six weeks' and two were of 12 weeks' duration; one study relates to a trial of 48 weeks, but only for a 16-week period before crossing over. The data for a number of outcomes could not be extracted. Four of the five included studies were based on a small number of participants.

The quality of the evidence available was judged very low to low, and the following findings should be interpreted cautiously. We found no evidence relating to clinical response in the short or medium term. At the end of six weeks, incidence of lethargy, hypersalivation, dizziness and tachycardia was lower at low-compared to standard-dose regimes; also side effects as measured by the Treatment Emergent Side Effect Scale (TESS) were less at low compared to standard dose. At six weeks, very low dose was associated with lower levels of blood glucose one hour post meal than standard dose and weight gain was the least in this group. At six weeks, standard dose was associated with lower serum triglycerides, serum total cholesterol and Apo-B than very low dose, and low-dose recipients had lower serum triglycerides than those on very low dose. This might suggest that the lipid variation may not be associated with doses of clozapine in the short term, such as six weeks' duration, but more trials are needed to validate the side effects of clozapine long term.

## **Overall completeness and applicability of evidence**

### **Completeness**

We suggest that the studies identified are insufficient to clearly identify what dose of clozapine is optimal for people suffering from schizophrenia and schizophreniform psychosis to gain a desired response to illness, attain remission and experience an improved quality of life. Important information on outcomes relevant to clinicians, consumers and policy makers (such as relapse, remission, social functioning and quality of life, service utilisation, cost-effectiveness, satisfaction with care, and quality of life) is not currently available.

### **Applicability**

The five studies in our review reported on 14 outcomes and only on short-term and medium-term durations. We could not identify any studies which compared high and very high doses of clozapine or which considered outcomes long term. This can lead to difficulties in generalising our findings in the management of chronic illness such as schizophrenia. The evidence appears to be incomplete and there are various limitations in the applicability of the results from our review.

### **Quality of the evidence**

The quality of the evidence was poor. Only one of the included studies was clearly described as a double blind trial; the other studies were not clear about blinding status. In addition, data were selectively reported in some papers, which raises the possibility of bias. The quality of the evidence was also limited by the small

number of participants reported on by [Simpson 1999](#) (n = 31), [Chen 2013](#) (n = 90), [Sheng 1990](#) (n = 51) and [Liu 2005](#) (n = 59). It is also of concern that two trials were conducted only for six weeks. Schizophrenia is a chronic illness and medications such as clozapine would need to be prescribed for a longer period of time so that these results may not generalise in the longer term. More good-quality trials are therefore needed to allow findings to be substantiated and firm conclusions to be drawn.

### Potential biases in the review process

We are not aware of any flaws in our review process. The search for trials was thorough and the review authors followed the criteria prespecified in the protocol. It is always possible, however, that we could have failed to identify relevant studies.

### Agreements and disagreements with other studies or reviews

To our knowledge there has been no other systematic review or meta-analysis comparing different doses of clozapine.

## AUTHORS' CONCLUSIONS

### Implications for practice

#### 1. For people with schizophrenia

We found no evidence relating dose to clinical response in the short or medium term. A standard dose (301 mg/day to 600 mg/day) helps in improvement of illness but causes more adverse effects than lower doses. Evidence from our review indicates that the very low dose of clozapine (< 150 mg/day) is associated with least side effects. Evidence supports that the low dose (150 mg/day to 300 mg/day) could be the optimal dose to see a clinical response with fewest side effects. Standard dose appears to be associated with more side effects than the other two groups which might necessitate close monitoring of weight, lipid profile and glucose. We could not reach a conclusion on high dose and very high dose of clozapine. Hence, in practice, every patient needs to be titrated on the most appropriate dose of clozapine necessary to gain a response, guided by close monitoring for emergence of side effects.

#### 2. For clinicians

Based on effects on mental state, we found no evidence on the optimal dosing of clozapine. Careful consideration has to be given to balancing the advantages and disadvantages of different dosing schemes, in particular in relation to side effects which seem to be

lower at lower doses. We were unable to identify any trials on high and very high doses of clozapine.

### 3. For managers or policy makers

More studies are needed to replicate and validate findings so far, and to ascertain effects on outcomes such as relapse, remission, social functioning, quality of life, service utilisation, cost-effectiveness, satisfaction with care, quality of life. There is a particular lack of medium- or long-term outcome data and on above-standard dosing regimes.

### Implications for research

#### 1. General

Much more data would have been available if the recommendations of the CONSORT statement had been anticipated by the trialists ([Moher 2001](#)). Allocation concealment is essential for the result of a trial to be considered valid and gives the assurance that selection bias is kept to the minimum. Well-described and tested blinding could have encouraged confidence in the control of performance and detection bias. It is also important to know how many, and from which groups, people were withdrawn in order to evaluate exclusion bias. It would also have been helpful if authors had presented data in a useful manner which reflects association between intervention and outcome, for example relative risk, odds ratio, risk or mean differences, as well as raw numbers. Binary outcomes should be calculated in preference to continuous results, as they are easier to interpret. If P values are used, the exact value should be reported.

#### 2. Specific

##### 2.1 Reviews

Inspection of the table of excluded studies does not suggest any particular need for additional review topics in relation to clozapine dose since data from any new eligible report will be included in updates of this review.

A number of the excluded studies examined adverse effects of clozapine at differing dose regimes, but could not be included because they reported results by serum clozapine level and not by clozapine dose. There may therefore be value in additionally reviewing those studies that focus on serum clozapine levels under a separate or modified protocol.

### Excluded studies in relation to other Cochrane Reviews

<i>Excluded study</i>	<i>Comparison</i>	<i>Existing Cochrane review</i>
<a href="#">de Leon 1995a</a>	Akathisia at three clozapine dose levels	None currently
<a href="#">de Leon 2003</a>	Muscarinic side effects at three clozapine dose levels	None currently
<a href="#">de Leon 2004</a>	Serum prolactin level at three clozapine dose levels	None currently
<a href="#">Han 2001</a>	Two different dose levels of clozapine with an adjunctive medication (sulpiride)	<a href="#">Wang 2010</a>
<a href="#">Liu 2005</a>	BPRS and TESS scores at three clozapine dose levels	None currently

### Clozapine dose for schizophrenia (Review)

<a href="#">Nair 1998</a>	Those with and without probable tardive dyskinesia at three clozapine dose levels	None currently
<a href="#">Nair 1999</a>	Those with and without probable tardive dyskinesia at three clozapine dose levels	None currently
<a href="#">Potkin 1993</a>	BPRS, CGI & EPS scores at two clozapine dose levels	None currently
<a href="#">Potkin 1994</a>	BPRS scores at two clozapine dose levels	None currently
<a href="#">Tang 2000</a>	Clinical response at three plasma clozapine concentration levels	None currently
<a href="#">VanderZwaag 1996</a>	BPRS scores at three different serum clozapine levels.	None currently
<a href="#">VanderZwaag 1997</a>	BPRS scores at three different serum clozapine levels.	None currently

## 2.2 Trials

Clozapine is usually reserved for people suffering from treatment-resistant illnesses. In spite of clozapine being in use for a very long time, there are still insufficient trials to clearly evidence which dose of clozapine is optimal for people suffering from schizophrenia and schizophreniform psychosis, to gain response to illness, attain remission and improve quality of life.

We consider an 'ideal' study might have the following characteristics.

- Participants: adults diagnosed with schizophrenia or schizoaffective disorder. Random allocation with 150 participants per arm and 100% follow-up.
- Intervention: three contrasting levels of clozapine dose – high (601 mg/day to 900 mg/day), standard (301 mg/day to 600 mg/day) and low (150 mg/day to 300 mg/day).

- Blinding: participants, clinical staff and researchers blinded to allocation status.
- Outcomes: functioning (clinically significant response in social or life skills), clinical response (e.g. clinically significant response in mental state), service utilisation (e.g. time to hospitalisation, number of days hospitalised), quality of life, relapse, satisfaction with care, and any clinically important adverse effects (e.g. weight gain, prolactin increase).

## ACKNOWLEDGEMENTS

The Cochrane Schizophrenia Group Editorial Base in Nottingham produces and maintains standard text for use in the Methods section of their reviews. We have used this text as the basis of what appears here and adapted it as required.

## REFERENCES

### References to studies included in this review

#### Chen 1998 {published data only}

Chen YG, Zhao JP, Xie GR, Chen JD, Zhu RH, Liao JD, et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. *Chinese Journal of Psychiatry* 1998;**31**(2):104-7.

#### Chen 2013 {published data only}

Chen YH, Cao Q, Chen WQ. The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. *Modern Diagnosis and Treatment [现代诊断与治疗]* 2013, issue 15:3460-1.

#### Liu 2005 {published data only}

Liu SF, Wang Y, Wang DP, Wei P, Wang SG, Ma HJ, et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. *Chinese Journal of New Drugs and Clinical Remedies* 2005;**24**(2):98-101.

Liu SF, Wei P, Wang SG, Wang DP, Wang Y, Ma HJ, et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. *Chinese Journal of Psychiatry* 2005;**38**(2):82-5.

#### Sheng 1990 {published data only}

Sheng XQ, Hua K, Yan H, Luo LH. Clozapine therapy in schizophrenia. *Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]* 1990; Vol. 16, issue 2:90-2.

#### Simpson 1999 {published data only}

Simpson GM. Correction. *American Journal of Psychiatry* 2001;**158**(5):834.

\* Simpson GM, Josiassen RC, Stanilla JK, de Leon J, Nair C, Abraham G, et al. Double blind study of clozapine dose response in chronic schizophrenia. *American Journal of Psychiatry* 1999;**156**(11):1744-50. [MEDLINE: 10553738]

de Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Weight gain during a double-blind multidose clozapine study. *Journal of Clinical Psychopharmacology* 2007;**27**(1):22-7. [MEDLINE: 17224708]

### References to studies excluded from this review

#### Borges 2010 {published data only}

Borges N, Sverdlhoff CE, Moreira R, Domingues C, Borges B, Lacerda A, et al. Evaluation by ancova of comparative bioavailability of two oral formulations of clozapine in steady state in schizophrenic volunteers under a different doses regime. *Clinical Pharmacology and Therapeutics* 2010;**87**(Suppl 1):S94.

#### de Leon 1995a {published data only}

de Leon J, Odom-White A, Stanilla J, Josiassen R, Simpson GM. Does clozapine induce akathisia?. *Schizophrenia Research* 1995;**15**(1-2):207.

#### de Leon 1995b {published data only}

Diaz FJ, De Leon J, Josiassen RC, Cooper TB, Simpson GM. Plasma clozapine concentration coefficients of variation in a long-term study. *Schizophrenia Research* 2005;**72**(2-3):131-5.

Nair C, Abraham G, Stanilla JK, Simpson GM, Josiassen RC. Tardive dyskinesia and extrapyramidal symptoms in treatment-resistant schizophrenics treated with clozapine. *Schizophrenia Research* 1997;**24**(1-2):272.

Simpson GM, Josiassen RC, Stanilla JK, de Leon J, Chand N, Abraham G, et al. "Double-blind study of clozapine dose response in chronic schizophrenia": correction. *American Journal of Psychiatry* 2001;**158**(5):834.

de Leon J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Does clozapine decrease smoking?. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 2005;**29**(5):757-62.

de Leon J, Diaz FJ, Wedlund P, Josiassen RC, Cooper TB, Simpson GM. Haloperidol half-life after chronic dosing. *Journal of Clinical Psychopharmacology* 2004;**24**(6):656-60.

#### de Leon 2003 {published data only}

de Leon J, Odom-White A, Josiassen RC, Diaz FJ, Cooper TB, Simpson GM. Serum antimuscarinic activity during clozapine treatment. *Journal of Clinical Psychopharmacology* 2003;**23**(4):336-41.

#### de Leon 2004 {published data only}

de Leon J, Diaz FJ, Josiassen RC, Simpson GM. Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. *European Archives of Psychiatry and Clinical Neuroscience* 2004;**254**(5):318-25. [MEDLINE: 15365707]

#### Guo 2003 {published data only}

Guo JY, Du QX. A study of beam changes after taking the different dosages of clozapine in patients with schizophrenic. *Medical Journal of Chinese People's Health [#####]* 2003;**15**(11):655-6.

#### Han 2001 {published data only}

Han YC, Shi SS, Xu RJ, Shang FZ. Controlled clinical trial of high versus low dose clozapine combined with sulpiride for schizophrenia. *Shandong Archives of Psychiatry [#####]* 2001;**14**(2):138-9.

#### Liu 2005a {published data only}

Liu SF, Mu JL, Zhang YJ, Wang SG, Wei P, Wang DP, et al. Effect of clozapine of different dosages on the cognitive function in patients with schizophrenia assessed by the changes of p300 potentials. *Chinese Journal of Clinical Rehabilitation* 2005;**9**(8):56-7.

#### Matz 1974 {published data only}

Matz R, Rick W, Thompson H, Gershon S. Clozapine - a potential antipsychotic agent without extrapyramidal manifestations.

*Current Therapeutic Research, Clinical and Experimental* 1974;**16**(7):687-95.

**McEvoy 1995** {published data only}

McEvoy J, Freudenreich O, McGee M, VanderZwaag C, Levin E, Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. *Biological Psychiatry* 1995;**37**(8):550-2.

McEvoy JP, VanderZwaag C, McGee M, Freudenreich O, Wilson WH, Cooper TB. A double blind, randomized trial comparing clozapine treatment within three distinct serum level ranges in patients with refractory chronic schizophrenia. *Schizophrenia Research* 1996;**22**(18):127.

**McEvoy 1996** {published data only}

McEvoy JP, Freudenreich O, Weiner RD. Clozapine-induced EEG changes as a function of clozapine serum levels. *Schizophrenia Research* 1996;**18**(2-3):233.

**Nair 1998** {published data only}

Nair CJ, de Leon J, Simpson GM, Josiassen RC. Therapeutic effects of clozapine on tardive dyskinesia. *Cognitive and Behavioral Practice* 1998;**5**:119-27.

**Nair 1999** {published data only}

Nair CJ, Josiassen RC, Abraham G, Stanilla JK, Tracy JI, Simpson GM. Does akathisia influence psychopathology in psychotic patients treated with clozapine?. *Biological Psychiatry* 1999;**45**:1376-83.

**Potkin 1993** {published data only}

Potkin SG, Bera R, Gulasekaram B. High and low dose of clozapine compared in a double-blind study. *Schizophrenia Research* 1993;**9**:246-7.

**Potkin 1994** {published data only}

Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. *Journal of Clinical Psychiatry* 1994;**55**(Suppl B):133-6. [MEDLINE: 7961557]

**Tang 2000** {published data only}

Tang Y, Peng C, Xiao H. Research for clozapine in schizophrenia and the relationship between plasma clozapine concentration and clinical response. *Journal of Clinical Psychological Medicine* [#####] 2000;**10**(6):335-7.

**VanderZwaag 1996** {published data only}

VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. *American Journal of Psychiatry* 1996;**153**(12):1579-84. [MEDLINE: 8942454]

**VanderZwaag 1997** {published and unpublished data}

Freudenreich O, Weiner RD, McEvoy JP. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. *Biological Psychiatry* 1997;**42**(2):132-7.

## References to studies awaiting assessment

**Abraham 1997** {published data only}

Abraham G, Nair C, Tracy JI, Simpson GM. The effects of clozapine on symptom clusters in treatment-refractory patients. *Journal of Clinical Psychopharmacology* 1997;**17**(1):49-53. [MEDLINE: 9004057]

## Additional references

**Aitchison 1997**

Aitchison K, Kerwin R. Cost-effectiveness of clozapine. A UK clinic-based study. *British Journal of Psychiatry* 1997;**171**:125-30.

**Altman 1996**

Altman DG, Bland JM. Detecting skewness from summary information. *BMJ* 1996;**313**(7066):1200. [OLZ020600]

**Arnt 1998**

Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. *Neuropsychopharmacology* 199;**8**(18):63-101.

**Asenjo 2010**

Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. Clozapine versus other atypical antipsychotics for schizophrenia. *Cochrane Database of Systematic Reviews* 2010, Issue 11. [DOI: [10.1002/14651858.CD006633.pub2](https://doi.org/10.1002/14651858.CD006633.pub2); PUBMED: 21069690]

**Azorin 2005**

Azorin JM, Kaladjian A, Fakra E. Current issues on schizoaffective disorder. *Encephale* 2005;**31**(3):359-65.

**Benazzi 2003**

Benazzi F. Outcome of schizophreniform disorder. *Current Psychiatry Reports* 2003;**5**(3):192-6.

**Bergem 1990**

Bergem AL, Dahl AA, Guldborg C, Hansen H. Langfeldt's schizophreniform psychoses fifty years later. *British Journal of Psychiatry* 1990;**157**:351-4.

**Bland 1997**

Bland JM. Statistics notes. Trials randomised in clusters. *BMJ* 1997;**315**:600.

**BNF 2012**

British National Formulary. Royal Pharmaceutical Society. London: BMJ Group, Pharmaceutical Press, Sep 2012:229-230.

**Boissel 1999**

Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Aperçu sur la problématique des indices d'efficacité thérapeutique, 3: comparaison des indices et utilisation. Groupe d'étude des Indices d'efficacité]. *Thérapie* 1999;**54**(4):405-11. [PUBMED: 10667106]



**Buchanan 1995**

Buchanan RW. Clozapine: efficacy and Safety. *Schizophrenia Bulletin* 1995;**21**(4):579-91.

**Carpenter 1994**

Carpenter WT Jr, Buchanan RW. Schizophrenia. *New England Journal of Medicine* 1994;**330**:681-90.

**Cipriani 2009**

Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. *Cochrane Database of Systematic Reviews* 2009, Issue 3. [DOI: [10.1002/14651858.CD006324.pub2](https://doi.org/10.1002/14651858.CD006324.pub2); PUBMED: 19588385]

**CMHP**

The College of Mental Health Pharmacy. [www.cmhp.org.uk](http://www.cmhp.org.uk) (accessed 5 August 2011).

**Coward 1992**

Coward DM. General pharmacology of clozapine. *British Journal of Psychiatry Supplement* 1992;**17**:5-11.

**Danileviciūte 2002**

Danileviciūte V. Schizoaffective disorder: clinical symptoms and present-day approach to treatment. *Medicina (Kaunas)* 2002;**38**(11):1057-65.

**Deeks 2000**

Deeks J. Issues in the selection for meta-analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.

**Deeks 2011**

Deeks JJ, Higgins JPT, Altman DG editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).

**Divine 1992**

Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. *Journal of General Internal Medicine* 1992;**7**(6):623-9.

**Donner 2002**

Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. *Statistics in Medicine* 2002;**21**(19):2971-80.

**DSM-IV**

American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR*. American Psychiatric Association, 2000.

**Egger 1997**

Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**(7109):629-34.

**Elbourne 2002**

Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthington HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. *International Journal of Epidemiology* 2002;**31**(1):140-9.

**Essali 2009**

Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. *Cochrane Database of Systematic Reviews* 2009, Issue 1. [DOI: [10.1002/14651858.CD000059.pub2](https://doi.org/10.1002/14651858.CD000059.pub2); PUBMED: 19160174]

**Furukawa 2006**

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. *Journal of Clinical Epidemiology* 2006;**59**(1):7-10.

**Gaebel 1997**

Gaebel W. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs. *International Clinical Psychopharmacology* 1997;**12**(Suppl 1):S37-42.

**Gelder 2001**

Gelder MJ, Mayou R, Cowen P. *Oxford Shorter Textbook of Psychiatry*. 4th Edition. New York, USA: Oxford University Press, 2001.

**Guldberg 1991**

Guldberg CA, Dahl AA, Hansen H, Bergem AL. Were Langfeldt's schizophreniform psychoses really affective?. *Psychopathology* 1991;**24**(5):270-6.

**Gulliford 1999**

Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. *American Journal of Epidemiology* 1999;**149**(9):876-83.

**Higgins 2003**

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557-60.

**Higgins 2011a**

Higgins JPT, Green S editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s). *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).

**Higgins 2011b**

Higgins JPT, Altman DG, Sterne JAC editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).

**Hutton 2009**

Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. *British Journal of Haematology* 2009;**146**(1):27-30.

**ICD-10**

World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. 10th Edition. World Health Organization, 2004.

**Kane 1988**

Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. *Archives of General Psychiatry* 1988;**45**(9):789-96.

**Kane 1990**

Kane JM. Treatment programme and long term outcome in chronic schizophrenia. *Acta Psychiatrica Scandinavica Supplementum* 1990;**358**:151-7.

**Kane 2011**

Kane JM. A user guide to clozapine. *Acta Psychiatrica Scandinavica* 2011; Vol. 123, issue 6:407-8.

**Kaplan 2005**

Sadock BJ, Sadock VA (editors). Kaplan & Sadock's Comprehensive Text Book of Psychiatry. 8th Edition. Philadelphia: Lippincott Williams & Wilkins, 2005.

**Kasanin 1933**

Kasanin J. The acute schizoaffective psychoses. *American Journal of Psychiatry* 1933;**90**:97-126.

**Kay 1986**

Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.

**Kerwin 2005**

Kerwin R, Bolonna A. Management of clozapine-resistant schizophrenia. *Advances in Psychiatric Treatment* 2005;**11**:101-106. [DOI: [10.1192/apt.11.2.101](https://doi.org/10.1192/apt.11.2.101)]

**Kronig 1995**

Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. *American Journal of Psychiatry* 1995;**152**:179-82.

**Lachar 2001**

Lachar D, Bailey SE, Rhoades HM, Espadas A, Aponte M, Cowan KA, et al. New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions. *Psychological Assessment* 2001;**13**(3):384-95.

**Leucht 2005a**

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores.

*British Journal of Psychiatry* 2005;**187**:366-71. [PUBMED: 16199797]

**Leucht 2005b**

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. *Schizophrenia Research* 2005;**79**(2-3):231-8. [PUBMED: 15982856]

**Leucht 2007**

Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. *Schizophrenia Bulletin* 2007;**33**(1):183-91. [PUBMED: 16905632]

**Marshall 2000**

Marshall M, Lockwood A, Bradley C, Adams CE, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. *British Journal of Psychiatry* 2000;**176**:249-52.

**McGrath 2008**

McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiologic Reviews* 2008;**30**:67-76. [DOI: [10.1093/epirev/mxn001](https://doi.org/10.1093/epirev/mxn001)]

**Meuser 2004**

Mueser KT, McGurk SR. Schizophrenia. *Lancet* 2004;**363**(9426):2063-72. [PUBMED: 15207959]

**Moher 2001**

Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *JAMA* 2001;**285**(15):1987-91.

**Naheed 2001**

Naheed M, Green B. Focus on clozapine. *Current Medical Research and Opinion* 2001;**17**(3):223-9.

**NICE**

National Institute for Health and Clinical Excellence (NICE). NICE clinical guideline 82: Schizophrenia core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. [www.nice.org.uk/guidance/CG82](http://www.nice.org.uk/guidance/CG82) (accessed 24 February 2017).

**NIMH 1985**

National Institute of Mental Health (NIMH). TESS (treatment emergent symptoms scale). *Psychopharmacology Bulletin* 1985;**22**:1069-72.

**Noreik 1967**

Noreik K, Astrup C, Dalgard OS, Holmboe R. A prolonged follow-up of acute schizophrenic and schizophreniform psychoses. *Acta Psychiatrica Scandinavica* 1967;**43**(4):432-43.

**Overall 1962**

Overall JE, Gorham DR. The brief psychiatric rating scale. *Psychological Reports* 1962;**10**:799-812.

**Saha 2005**

Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. *PLoS Medicine* 2005;**2**(5):e141.

**Schünemann 2011**

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S editor(s), *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.cochrane-handbook.org](http://www.cochrane-handbook.org).

**Semple 2007**

Smyth R, Burns J, Darjee R, McIntosh A. *Oxford Handbook of Psychiatry*. New York: Oxford University Press Inc., 2007.

**Simpson 2001**

Simpson GM. Correction. *American Journal of Psychiatry* 2001;**158**(5):834.

**Stahl 2006**

Stahl SM. *Essential Psychopharmacology*. Cambridge, New York, USA: Cambridge University Press, 2006.

**Sterne 2011**

Sterne JAC, Egger M, Moher D editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). *Cochrane Handbook for Systematic Reviews of Intervention*. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).

**Syed 2008**

Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, et al. Pharmacological interventions for clozapine-induced hypersalivation. *Cochrane Database of Systematic Reviews* 2008, Issue 3. [DOI: [10.1002/14651858.CD005579.pub2](https://doi.org/10.1002/14651858.CD005579.pub2); PUBMED: 18646130]

**Taylor 1995**

Taylor D, Duncan D. The use of clozapine plasma levels in optimising therapy. *Psychiatric Bulletin* 1995;**19**:753-55.

**Ukoumunne 1999**

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based

intervention in health and health care: a systematic review. *Health Technology Assessment* 1999;**3**(5):1-75.

**van Os 2009**

van Os J, Kapur S. Schizophrenia. *Lancet* 2009;**374**(9690):635-45. [PUBMED: 19700006]

**Vieta 2010**

Vieta E. Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation. *Journal of Clinical Psychiatry* 2010;**71**(Suppl 2):14-9.

**Wang 2004**

Wang PS, Ganz DA, Benner JS, Glynn RJ, Avorn J. Should clozapine continue to be restricted to third-line status for schizophrenia?: A decision-analytic model. *Journal of Mental Health Policy and Economics* 2004;**7**(2):77-85.

**Wang 2010**

Wang J, Omori IM, Fenton M, Soares BGO. Sulpiride augmentation for schizophrenia. *Cochrane Database of Systematic Reviews* 2010, Issue 1. [DOI: [10.1002/14651858.CD008125.pub2](https://doi.org/10.1002/14651858.CD008125.pub2)]

**WHO 2013**

World Health Organisation. Health topics, mental health, schizophrenia. [www.who.int/mental\\_health/management/schizophrenia/en/](http://www.who.int/mental_health/management/schizophrenia/en/) (accessed 9 March 2013).

**Woerner 1988**

Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. *Psychopharmacology Bulletin* 1988;**24**(1):112-7.

**Xia 2009**

Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. *Psychiatric Bulletin* 2009;**33**(7):254-7.

\* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

**Chen 1998**

Methods	Allocation: randomly assigned (no further details). Blinding: not stated. Duration: six weeks. Setting: unclear.
Participants	Diagnosis: schizophrenia. N = 176. Age: 17 to 55 years. Sex: male and female (numbers not given) Racial origin: unclear. Consent: unclear. History: Average length of illness: 8 ± 11months.

**Clozapine dose for schizophrenia (Review)**

**Chen 1998** (Continued)

Interventions	1. Clozapine: dose 200 mg/day. N = 94. 2. Clozapine: dose 500 mg/day. N = 82.
Outcomes	Global state: Clinically important response as defined by individual studies (BPRS score > 30% change). Mental state: average endpoint score and average change score B (BPRS-A). Adverse effects: TESS scores, lethargy, hypersalivation, dizziness, tachycardia.  Leaving the study early.
Notes	

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomly assigned, no further details.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not stated.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All data reported; no loss to follow up.
Selective reporting (reporting bias)	Low risk	No indication of selective reporting.
Other bias	Unclear risk	Sponsor unclear.

**Chen 2013**

Methods	Allocation: randomised, method not stated Blinding: double blind, no further details Duration: twelve weeks. Setting: not stated
Participants	Patients with schizophrenia (inpatients; male & female)
Interventions	1. Clozapine: dose 200-300 mg/day. N = 30 2. Clozapine: dose 301-400 mg/day. N = 30 3. Clozapine: dose 401-500 mg/day. N = 30  Initial dose 25 mg/day in all cases: doses above achieved at 2-3 weeks
Outcomes	Mental state: Clinical improvement, clinician assessed

**Clozapine dose for schizophrenia (Review)**

**Chen 2013** (Continued)

Adverse effects: TESS scale score

Notes

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomly assigned, no further details.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not stated.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All data reported; no loss to follow up.
Selective reporting (reporting bias)	Low risk	No indication of selective reporting.
Other bias	Unclear risk	Sponsor unclear.

**Liu 2005**

Methods	Allocation: randomised using random number table Blinding: not stated. Duration: six weeks. Setting: inpatient setting at a medical College.
Participants	Diagnosis: schizophrenia (CCMD-3) N = 87. Age: 18 to 45 years. Sex: 87 M. Racial origin: unclear. Consent: unclear. History: information not available.
Interventions	1. Clozapine: dose < 150 mg/day. N = 30. 2. Clozapine: dose 150 to 300 mg/day. N = 29. 3. Clozapine: dose > 300 mg/day. N = 28.
Outcomes	Adverse effects: serum lipid level before and after treatment, body weight, BMI. Leaving the study early*.
Notes	* Standard dose group: two participants left the study early (due to neutropenia and

**Clozapine dose for schizophrenia (Review)**

**Liu 2005** (Continued)

tachycardia). Low dose group: one participant left the study early (due to increased level of Alanine aminotransferase).

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Allocation by random number table.
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not stated.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Three participants left the study early, reasons given.
Selective reporting (reporting bias)	Low risk	No indication of selective reporting.
Other bias	Low risk	No indication of other bias.

**Sheng 1990**

Methods	Allocation: randomised, method not stated. Blinding: double blind, no further details. Duration: twelve weeks. Setting: not stated.
Participants	Patients with schizophrenia (inpatients; male & female).
Interventions	1.Clozapine (capsule): dose 300 mg/day. N = 25. 2.Clozapine (capsule): dose 600 mg/day. N = 26.
Outcomes	Mental state: Clinical improvement, clinician assessed. Mental state: BPRS score (data not available). Adverse effects: TESS scale score (data not available).
Notes	

**Risk of bias**

Bias	Authors' judgement	Support for judgement
------	--------------------	-----------------------

**Clozapine dose for schizophrenia (Review)**

**Sheng 1990** (Continued)

Random sequence generation (selection bias)	Unclear risk	Randomly assigned, no further details.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	'Double blind', no further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	'Double blind', no further details.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All data reported; no loss to follow-up.
Selective reporting (reporting bias)	High risk	BPRS and TESS score data not available.
Other bias	Unclear risk	Sponsor unclear.

**Simpson 1999**

Methods	<p>Allocation: implied randomisation trial, no details on method of allocation.</p> <p>Blindness: double-blind, assessors blind to clozapine doses.</p> <p>Duration: 16 weeks (first phase before cross over lasted 16 weeks; total of three phases lasting 48 weeks).</p> <p>Setting: Research ward, State Hospital Clinical Research Centre, USA.</p>
Participants	<p>Diagnosis: treatment refractory schizophrenia or schizoaffective disorder (DSM-III-R).        N = 48 (number who completed first 16 weeks before any cross-over).        Age: 35 to 54 years.        Sex: M 22, F 28.        Racial origin: Caucasian 43, African American 7.</p> <p>Consent: signed informed consent.</p> <p>History: average length of illness: mean 25.1 years (range 1 to 38 years), median of five psychiatric hospitalizations (range 1 to 25); patients had not shown satisfactory clinical response to treatment with at least three antipsychotic drugs (each given for at least six weeks in doses equivalent to 1000 mg/day of chlorpromazine).</p>
Interventions	<ol style="list-style-type: none"> <li>1. Clozapine: dose 100 mg/day. N = 14.</li> <li>2. Clozapine: dose 300 mg/day. N = 17.</li> <li>3. Clozapine: dose 600 mg/day. N = 17.</li> </ol>
Outcomes	<p>Mental state: (BPRS-A) total score.</p> <p>Leaving the study early.</p>
Notes	<ol style="list-style-type: none"> <li>1. Patients stayed in research centre for four weeks for adaptation (naturalistic baseline with no modification in their treatment regimen). Before first phase of clozapine treatment, patients underwent a four-week haloperidol treatment and then a one-week wash out. We contacted the main trialist to obtain missing data on CGI, SANS, responders at 16 weeks, and on which dosage group the four responders belonged to but we have not received results at the time of writing.</li> </ol>

**Clozapine dose for schizophrenia (Review)**

**Simpson 1999** (Continued)

2. data from [Simpson 1999](#) have been adjusted in accordance with the published corrections ([Simpson 2001](#)). Specifically, the standard errors for BPRS-A endpoint scores which were originally reported by the authors as if they were standard deviations have been converted to standard deviations.

**Risk of bias**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Implied randomisation trial, no details on method of allocation.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants were blinded to doses of clozapine; no details on personnel giving the treatment.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessors were blinded to doses of clozapine.
Incomplete outcome data (attrition bias) All outcomes	High risk	44 out of 48 patients completed the first 16 weeks of the trial; four patients had their last observation carried forward. If a patient had attained the maximum assigned dose for two weeks, his or her data were carried forward for end-point analysis. However, as clozapine can take more time to exert its effect, if the patient leaves the study soon after two weeks, the last observation carried forward might underestimate the efficiency of that particular dose of clozapine.
Selective reporting (reporting bias)	High risk	Responders' data reported at 48 weeks, but not at end of 16 weeks and 32 weeks by dose; CGI, SANS not reported.
Other bias	High risk	Sponsored by Novartis Pharmaceuticals.

BPRS: Brief Psychiatric Rating Scale

BPRS-A: Brief Psychiatric Rating Scale - Anchored

**Characteristics of excluded studies** [ordered by study ID]

Study	Reason for exclusion
<a href="#">Borges 2010</a>	Allocation: random allocation.  Participants: all had schizophrenia.  Intervention: examined bioavailability at a clozapine dose regime of between 200 mg/day and 800 mg/day.  Outcome: no additional data for this review; study examined only the bioavailability of clozapine.
<a href="#">de Leon 1995a</a>	Allocation: method of allocation unclear.  Participants: all had schizophrenia or schizoaffective disorder.  Intervention: compared akathisia at three clozapine doses of 100mg/day, 300mg/day & 600mg/day.



Study	Reason for exclusion
	Outcomes: Barnes akathisia scale endpoint and change scores unavailable.
de Leon 1995b	<p>Allocation: random allocation.</p> <p>Participants: all had treatment refractory schizophrenia or schizoaffective disorder.</p> <p>Intervention: three clozapine doses of 100 mg/day, 300 mg/day and 600 mg/day.</p> <p>Outcome: no additional data for this review; these 4 studies examined (a) relationship between tardive dyskinesia and extrapyramidal symptoms, (b) coefficients of variation in the relationship between dose and plasma concentration levels, (c) plasma cotinine levels, and (d) effects of haloperidol.</p>
de Leon 2003	<p>Allocation: method of allocation unclear.</p> <p>Participants: all had schizophrenia or schizoaffective disorder.</p> <p>Intervention: compared muscarinic side effects at three clozapine doses of 100mg/day, 300mg/day &amp; 600mg/day.</p> <p>Outcomes: no usable data before the first cross-over.</p>
de Leon 2004	<p>Allocation: method of allocation unclear.</p> <p>Participants: all had schizophrenia or schizoaffective disorder.</p> <p>Intervention: compared serum prolactin level at three clozapine doses of 100mg/day, 300mg/day &amp; 600mg/day.</p> <p>Outcomes: no usable data before the first cross-over.</p>
Guo 2003	<p>Allocation: non-randomized controlled trial.</p> <p>Participants: all had schizophrenia.</p> <p>Intervention: studied BEAM changes after taking three different dosages of clozapine: &lt; 150 mg/day vs 150 mg/day to 400 mg/day vs &gt; 400 mg/day.</p> <p>Outcomes: BEAM changes.</p>
Han 2001	<p>Allocation: random allocation.</p> <p>Participants: all had schizophrenia.</p> <p>Intervention: two clozapine doses of &lt; 300mg/day &amp; &gt; 300mg/day, but adjunctive medication (sulpiride) not held constant between different clozapine dosage groups.</p> <p>Outcomes: compared BPRS and TESS scores between groups.</p>
Liu 2005a	<p>Allocation: not allocated at random.</p> <p>Participants: all had schizophrenia.</p> <p>Intervention: three different clozapine doses.</p> <p>Outcomes: compared PANSS scores and p300 test results.</p>
Matz 1974	<p>Allocation: not randomised; allocation at discretion of psychiatrists in charge.</p> <p>Participation: all had schizophrenia.</p> <p>Intervention: examined effects of clozapine at two doses (up to 100 mg t.i.d. and up to 400 mg t.i.d.).</p>

Study	Reason for exclusion
	Outcome: BPRS and NOSIE, plus TES for adverse effects.
McEvoy 1995	<p>Allocation: random allocation.</p> <p>Participants: all had schizophrenia.</p> <p>Intervention: examined BPRS, CGI, smoking measures &amp; EEG changes at three clozapine serum level ranges (50 ng/mL to 150 ng/mL, 200 ng/mL to 300 ng/mL &amp; 350 ng/mL to 450ng/mL).</p> <p>Outcome: no additional data for this review; comparison was by serum clozapine level, and not by clozapine dose.</p>
McEvoy 1996	<p>Allocation: random allocation.</p> <p>Participants: all had chronic schizophrenia.</p> <p>Intervention: examined smoking measures at three clozapine serum level ranges (50 ng/mL to 150ng/mL, 200 ng/mL to 300ng/mL &amp; 350 ng/mL to 450ng/mL).</p> <p>Outcome: no additional data for this review; comparison was by serum clozapine level, and not by clozapine dose.</p>
Nair 1998	<p>Allocation: random allocation.</p> <p>Participants: all had treatment refractory schizophrenia or schizoaffective disorder.</p> <p>Intervention: three clozapine doses of 100 mg/day, 300 mg/day and 600 mg/day.</p> <p>Outcome: no additional data; study compared those with and without probable tardive dyskinesia in a subgroup of 23 participants from the <a href="#">Simpson 1999</a> trial.</p>
Nair 1999	<p>Allocation: random allocation.</p> <p>Participants: all had treatment refractory schizophrenia or schizoaffective disorder.</p> <p>Intervention: three clozapine doses of 100 mg/day, 300 mg/day and 600 mg/day.</p> <p>Outcome: no additional data; study compared those with and without probable tardive dyskinesia in a subgroup of 33 participants from the <a href="#">Simpson 1999</a> trial.</p>
Potkin 1993	<p>Allocation: random allocation.</p> <p>Participants: all had chronic schizophrenia.</p> <p>Intervention: compared BPRS, CGI &amp; EPS scores at two clozapine doses of 400mg/day &amp; 800mg/day.</p> <p>Outcomes: data limited to the 'first 25' patients with no information on which dosage group they belonged to; attempts to contact first author unsuccessful.</p>
Potkin 1994	<p>Allocation: random allocation.</p> <p>Participants: all had schizophrenia.</p> <p>Intervention: clozapine commenced at 400 mg/day with participants randomised at end of week four to 400mg/day or 800mg/day. Study compared dosage groups on BPRS scores and numbers discontinuing in the first three weeks.</p> <p>Outcomes: compared BPRS scores by serum clozapine level, and not by clozapine dose; attempts to contact first author unsuccessful.</p>
Tang 2000	Allocation: not randomly allocated.

Study	Reason for exclusion
	<p>Participants: all had schizophrenia.</p> <p>Intervention: examined the relationship between plasma clozapine concentration and clinical response.</p>
VanderZwaag 1996	<p>Allocation: random allocation.</p> <p>Participants: all had chronic schizophrenia.</p> <p>Intervention: examined the change in BPRS and SANS scores at three different serum clozapine levels.</p> <p>Outcomes: compared BPRS scores by serum clozapine level, and not by clozapine dose.</p>
VanderZwaag 1997	<p>Allocation: random allocation.</p> <p>Participants: all had chronic schizophrenia.</p> <p>Intervention: examined the change in EEG at three different serum clozapine levels.</p> <p>Outcomes: compared BPRS scores by serum clozapine level, and not by clozapine dose.</p>

### Characteristics of studies awaiting assessment [ordered by study ID]

#### Abraham 1997


Methods	<p>Allocation: unclear, no details.</p> <p>Blindness: double-blind, rated independently.</p> <p>Duration: 16 weeks.</p> <p>Setting: inpatient.</p>
Participants	<p>Diagnosis: treatment resistant schizophrenia or schizoaffective disorder (DSM-III-R).            N = 30.            Age: 35 to 53 years.            Sex: M 17, F 13.</p> <p>Racial origin: not stated.            Consent: signed informed consent.            History: Average length of illness: 24.9 years (range 16.1 to 33.7 years).</p>
Interventions	<ol style="list-style-type: none"> <li>1. Clozapine: dose 100 mg/day.</li> <li>2. Clozapine: dose 300 mg/day.</li> <li>3. Clozapine: dose 600 mg/day.</li> </ol>
Outcomes	None.
Notes	<p>This report presents additional results from the <a href="#">Simpson 1999</a> trial. Patients were allowed to adapt to new clinical environment for minimum of four weeks, followed by four weeks of haloperidol treatment and a one-week wash-out period. Participants who were randomised to 300 mg/day or 600 mg/day of clozapine were subsequently categorised as “improvers” or “non-improvers” based on change in CGI scores, and these groups were compared on demographics, baseline characteristics and BPRS scores. No information was given, however, on the dosage group to which the improvers and non-improvers belonged. We contacted the lead author who agreed to send the missing data, but at the time of writing this had not been received. If we subsequently receive this data, we will include it in future versions of this review.</p>

**DATA AND ANALYSES**
**Comparison 1. CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day)**


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mental state: Average end-point score (BPRS-A, high = poor) - medium term	1	31	Mean Difference (IV, Random, 95% CI)	3.55 [-4.50, 11.60]
2 Adverse effects: 1a. Weight - BMI - short term	1	59	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.95, 0.75]
3 Adverse effects: 1b. Weight - weight gain	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1 short term	1	27	Mean Difference (IV, Random, 95% CI)	-1.1 [-3.93, 1.73]
3.2 medium term	1	28	Mean Difference (IV, Random, 95% CI)	-1.3 [-4.86, 2.26]
4 Adverse effects: 1c. Weight - body weight at endpoint - short term	1	59	Mean Difference (IV, Random, 95% CI)	0.0 [-3.92, 3.92]
5 Adverse effects: 2a. Metabolic - blood glucose - short term	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
5.1 Before meal	1	59	Mean Difference (IV, Random, 95% CI)	-0.40 [-1.06, 0.26]
5.2 1 hour after meal	1	59	Mean Difference (IV, Random, 95% CI)	-0.70 [-2.01, 0.61]
5.3 2 hours after meal	1	59	Mean Difference (IV, Random, 95% CI)	0.30 [-0.98, 1.58]
5.4 3 hours after meal	1	59	Mean Difference (IV, Random, 95% CI)	-0.70 [-1.59, 0.19]
6 Adverse effects: 2b. Metabolic - lipid profile - short term	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
6.1 triglycerides	1	59	Mean Difference (IV, Random, 95% CI)	1.00 [0.51, 1.49]
6.2 cholesterol - total	1	59	Mean Difference (IV, Random, 95% CI)	0.50 [-0.12, 1.12]
6.3 lipoprotein - high density (HDL)	1	59	Mean Difference (IV, Random, 95% CI)	0.04 [-0.14, 0.22]
6.4 lipoprotein - low density (LDL)	1	59	Mean Difference (IV, Random, 95% CI)	0.10 [-0.36, 0.56]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
6.5 Apo A-1	1	59	Mean Difference (IV, Random, 95% CI)	0.05 [-0.10, 0.20]
6.6 Apo-B	1	59	Mean Difference (IV, Random, 95% CI)	0.13 [-0.16, 0.42]
<b>7 Leaving the study early</b>	<b>2</b>	<b>91</b>	<b>Risk Ratio (M-H, Random, 95% CI)</b>	<b>1.50 [0.09, 25.41]</b>
7.1 any reason - medium term	1	31	Risk Ratio (M-H, Random, 95% CI)	6.0 [0.31, 115.56]
7.2 specific reason (alanine aminotransferase level) - short term	1	60	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.01, 7.87]


**Analysis 1.1. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 1 Mental state: Average endpoint score (BPRS-A, high = poor) - medium term.**




**Analysis 1.2. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 2 Adverse effects: 1a. Weight - BMI - short term.**




**Analysis 1.3. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 3 Adverse effects: 1b. Weight - weight gain.**







**Analysis 1.4. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 4 Adverse effects: 1c. Weight - body weight at endpoint - short term.**




**Analysis 1.5. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 5 Adverse effects: 2a. Metabolic - blood glucose - short term.**





**Analysis 1.6. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 6 Adverse effects: 2b. Metabolic - lipid profile - short term.**



Study or subgroup	very low dose		low dose		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			

Test for subgroup differences: Chi<sup>2</sup>=15.42, df=1 (P=0.01), I<sup>2</sup>=67.57%

Favours very low dose    -100    -50    0    50    100    Favours low dose

**Analysis 1.7. Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 7 Leaving the study early.**

Study or subgroup	very low dose n/N	low dose n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M-H, Random, 95% CI
Simpson 1999	2/14	0/17		51.94%	6[0.31,115.56]
<b>Subtotal (95% CI)</b>	<b>14</b>	<b>17</b>		<b>51.94%</b>	<b>6[0.31,115.56]</b>
Total events: 2 (very low dose), 0 (low dose)					
Heterogeneity: Not applicable					
Test for overall effect: Z=1.19(P=0.24)					
<b>1.7.2 specific reason (alanine aminotransferase level) - short term</b>					
Liu 2005	0/30	1/30		48.06%	0.33[0.01,7.87]
<b>Subtotal (95% CI)</b>	<b>30</b>	<b>30</b>		<b>48.06%</b>	<b>0.33[0.01,7.87]</b>
Total events: 0 (very low dose), 1 (low dose)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.68(P=0.5)					
<b>Total (95% CI)</b>	<b>44</b>	<b>47</b>		<b>100%</b>	<b>1.5[0.09,25.41]</b>
Total events: 2 (very low dose), 1 (low dose)					
Heterogeneity: Tau <sup>2</sup> =1.74; Chi <sup>2</sup> =1.71, df=1(P=0.19); I <sup>2</sup> =41.68%					
Test for overall effect: Z=0.28(P=0.78)					
Test for subgroup differences: Chi <sup>2</sup> =1.71, df=1 (P=0.19), I <sup>2</sup> =41.59%					

Favours very low dose    0.001    0.1    1    10    1000    Favours low dose


**Comparison 2. CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day)**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mental state: 1a. Average endpoint score (BPRS-A, high = poor) - medium term	1	31	Mean Difference (IV, Random, 95% CI)	6.67 [-2.09, 15.43]
2 Adverse effects: 1a. Weight - BMI - short term	1	58	Mean Difference (IV, Random, 95% CI)	0.10 [-0.76, 0.96]
3 Adverse effects: 1b. Weight - weight gain	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1 short term	1	27	Mean Difference (IV, Random, 95% CI)	-2.70 [-5.38, -0.02]
3.2 medium term	1	28	Mean Difference (IV, Random, 95% CI)	-3.10 [-6.73, 0.53]




Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4 Adverse effects: 1c. Weight - body weight at endpoint - short term	1	58	Mean Difference (IV, Random, 95% CI)	1.0 [-2.66, 4.66]
5 Adverse effects: 2a. Metabolic - blood glucose - short term	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
5.1 one hour after meal	1	58	Mean Difference (IV, Random, 95% CI)	-1.60 [-2.90, -0.30]
5.2 before meal	1	58	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.68, 0.48]
5.3 two hours after meal	1	58	Mean Difference (IV, Random, 95% CI)	-0.60 [-1.89, 0.69]
5.4 three hours after meal	1	58	Mean Difference (IV, Random, 95% CI)	-0.30 [-1.55, 0.95]
6 Adverse effects: 2b. Metabolic - lipid profile - short term	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
6.1 cholesterol - total	1	58	Mean Difference (IV, Random, 95% CI)	1.00 [0.20, 1.80]
6.2 triglycerides	1	58	Mean Difference (IV, Random, 95% CI)	1.30 [0.81, 1.79]
6.3 Apo - B	1	58	Mean Difference (IV, Random, 95% CI)	0.23 [0.01, 0.45]
6.4 lipoprotein - high density (HDL)	1	58	Mean Difference (IV, Random, 95% CI)	0.10 [-0.13, 0.33]
6.5 lipoprotein - low density (LDL)	1	58	Mean Difference (IV, Random, 95% CI)	0.0 [-0.39, 0.39]
6.6 Apo A -1	1	58	Mean Difference (IV, Random, 95% CI)	0.04 [-0.10, 0.18]
7 Leaving the study early	2	91	Risk Ratio (M-H, Random, 95% CI)	0.73 [0.14, 3.72]
7.1 any reason - medium term	1	31	Risk Ratio (M-H, Random, 95% CI)	1.21 [0.20, 7.55]
7.2 specific reason (neutropenia and tachycardia) - short term	1	60	Risk Ratio (M-H, Random, 95% CI)	0.2 [0.01, 4.00]


**Analysis 2.1. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 1 Mental state: 1a. Average endpoint score (BPRS-A, high = poor) - medium term.**




**Analysis 2.2. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 2 Adverse effects: 1a. Weight - BMI - short term.**




**Analysis 2.3. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 3 Adverse effects: 1b. Weight - weight gain.**




**Analysis 2.4. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 4 Adverse effects: 1c. Weight - body weight at endpoint - short term.**




**Analysis 2.5. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 5 Adverse effects: 2a. Metabolic - blood glucose - short term.**





**Analysis 2.6. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 6 Adverse effects: 2b. Metabolic - lipid profile - short term.**





**Analysis 2.7. Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301-600 mg/day), Outcome 7 Leaving the study early.**






**Comparison 3. CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)**

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mental state: 1a. Clinically important response as (BPRS score > 30% change)	1	176	Risk Ratio (M-H, Fixed, 95% CI)	0.93 [0.78, 1.10]
2 Mental state: 1b. Average endpoint score (BPRS-A total, high = poor)	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
2.1 short term	1	176	Mean Difference (IV, Random, 95% CI)	1.70 [-1.26, 4.66]
2.2 medium term	1	34	Mean Difference (IV, Random, 95% CI)	3.12 [-4.20, 10.44]
3 Mental state: 1c. Average endpoint score (BPRS-A subscores, high = poor) - short term	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 anxiety	1	176	Mean Difference (IV, Fixed, 95% CI)	0.0 [-0.09, 0.09]
3.2 blunted affect	1	176	Mean Difference (IV, Fixed, 95% CI)	0.0 [-0.18, 0.18]
3.3 conceptual disorganisation	1	176	Mean Difference (IV, Fixed, 95% CI)	0.20 [-0.02, 0.42]
3.4 excitement	1	176	Mean Difference (IV, Fixed, 95% CI)	0.0 [-0.10, 0.10]
3.5 uncooperativeness	1	176	Mean Difference (IV, Fixed, 95% CI)	0.0 [-0.21, 0.21]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4 Mental state: 1e. Clinical improvement, clinician assessed	2	141	Risk Ratio (M-H, Random, 95% CI)	0.76 [0.36, 1.61]
5 Adverse effects: 1a. Weight - BMI - short term	1	57	Mean Difference (IV, Random, 95% CI)	0.20 [-0.84, 1.24]
6 Adverse effects: 1b. Weight - weight gain	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
6.1 short term	1	165	Mean Difference (IV, Random, 95% CI)	-1.60 [-3.81, 0.61]
6.2 medium term	1	30	Mean Difference (IV, Random, 95% CI)	-1.80 [-5.38, 1.78]
7 Adverse effects: 1c. Weight - body weight at endpoint - short term	1	57	Mean Difference (IV, Random, 95% CI)	1.0 [-3.42, 5.42]
8 Adverse effects: 2a. Metabolic - blood glucose - short term	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
8.1 before meal	1	57	Mean Difference (IV, Random, 95% CI)	0.30 [-0.23, 0.83]
8.2 one hour after meal	1	57	Mean Difference (IV, Random, 95% CI)	-0.90 [-2.33, 0.53]
8.3 two hours after meal	1	58	Mean Difference (IV, Random, 95% CI)	-0.90 [-2.14, 0.34]
8.4 three hours after meal	1	57	Mean Difference (IV, Random, 95% CI)	0.40 [-0.84, 1.64]
9 Adverse effects: 2b. Metabolic - lipid profile - short term	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
9.1 cholesterol - total	1	57	Mean Difference (IV, Random, 95% CI)	0.5 [-0.29, 1.29]
9.2 triglycerides	1	57	Mean Difference (IV, Random, 95% CI)	0.30 [-0.12, 0.72]
9.3 lipoprotein - high density (HDL)	1	57	Mean Difference (IV, Random, 95% CI)	0.06 [-0.16, 0.28]
9.4 lipoprotein - low density (LDL)	1	57	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.50, 0.30]
9.5 Apo A -1	1	57	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.14, 0.12]
9.6 Apo - B	1	57	Mean Difference (IV, Random, 95% CI)	0.10 [-0.14, 0.34]




**Analysis 3.2. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 2 Mental state: 1b. Average endpoint score (BPRS-A total, high = poor).**




**Analysis 3.3. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 3 Mental state: 1c. Average endpoint score (BPRS-A subscores, high = poor) - short term.**









**Analysis 3.4. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 4 Mental state: 1e. Clinical improvement, clinician assessed.**



**Analysis 3.5. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 5 Adverse effects: 1a. Weight - BMI - short term.**



**Analysis 3.6. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 6 Adverse effects: 1b. Weight - weight gain.**



Study or subgroup	low dose		standard dose		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
Heterogeneity: Not applicable							
Test for overall effect: Z=0.99(P=0.32)							
Test for subgroup differences: Chi <sup>2</sup> =0.01, df=1 (P=0.93), I <sup>2</sup> =0%							
Favours low dose    -100    -50    0    50    100    Favours standard dose							


**Analysis 3.7. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 7 Adverse effects: 1c. Weight - body weight at endpoint - short term.**

Study or subgroup	low dose		standard dose		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
Liu 2005	29	69 (9)	28	68 (8)		100%	1[-3.42,5.42]
<b>Total ***</b>	<b>29</b>		<b>28</b>			<b>100%</b>	<b>1[-3.42,5.42]</b>
Heterogeneity: Not applicable							
Test for overall effect: Z=0.44(P=0.66)							
Favours low dose    -100    -50    0    50    100    Favours standard dose							


**Analysis 3.8. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 8 Adverse effects: 2a. Metabolic - blood glucose - short term.**


Study or subgroup	low dose		standard dose		Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% CI
	N	Mean(SD)	N	Mean(SD)			
<b>3.8.1 before meal</b>							
Liu 2005	29	5.1 (1.2)	28	4.8 (0.8)		100%	0.3[-0.23,0.83]
<b>Subtotal ***</b>	<b>29</b>		<b>28</b>			<b>100%</b>	<b>0.3[-0.23,0.83]</b>
Heterogeneity: Not applicable							
Test for overall effect: Z=1.11(P=0.27)							
<b>3.8.2 one hour after meal</b>							
Liu 2005	29	8.8 (2.8)	28	9.7 (2.7)		100%	-0.9[-2.33,0.53]
<b>Subtotal ***</b>	<b>29</b>		<b>28</b>			<b>100%</b>	<b>-0.9[-2.33,0.53]</b>
Heterogeneity: Not applicable							
Test for overall effect: Z=1.24(P=0.22)							
<b>3.8.3 two hours after meal</b>							
Liu 2005	29	7 (2.4)	29	7.9 (2.4)		100%	-0.9[-2.14,0.34]
<b>Subtotal ***</b>	<b>29</b>		<b>29</b>			<b>100%</b>	<b>-0.9[-2.14,0.34]</b>
Heterogeneity: Not applicable							
Test for overall effect: Z=1.43(P=0.15)							
<b>3.8.4 three hours after meal</b>							
Liu 2005	29	6.2 (1.7)	28	5.8 (2.9)		100%	0.4[-0.84,1.64]
<b>Subtotal ***</b>	<b>29</b>		<b>28</b>			<b>100%</b>	<b>0.4[-0.84,1.64]</b>
Heterogeneity: Not applicable							
Test for overall effect: Z=0.63(P=0.53)							
Test for subgroup differences: Chi <sup>2</sup> =5.14, df=1 (P=0.16), I <sup>2</sup> =41.63%							
Favours low dose    -4    -2    0    2    4    Favours standard dose							

**Analysis 3.9. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 9 Adverse effects: 2b. Metabolic - lipid profile - short term.**





**Analysis 3.10. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 10 Adverse effects: 3. Various effects - short term.**






**Analysis 3.11. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 11 Adverse effects: 4. Average endpoint scores (TESS, high = poor) - short term.**





**Analysis 3.12. Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 12 Leaving the study early.**



**ADDITIONAL TABLES**

**Table 1. Other reviews in the clozapine series**

Title	Reference
Clozapine versus other atypical antipsychotics for schizophrenia	<a href="#">Asenjo 2010</a>
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia	<a href="#">Cipriani 2009</a>
Clozapine versus typical neuroleptic medication for schizophrenia	<a href="#">Essali 2009</a>
Pharmacological interventions for clozapine-induced hypersalivation	<a href="#">Syed 2008</a>

## APPENDICES

### Appendix 1. Previous searches

#### Search in 2011

##### Electronic searches

##### Cochrane Schizophrenia Group Trials Register

We searched the register (August 2011) using the following phrase:

[(*\*clozapin\* or \*clozaril\* or \*leponex\* or \*denzapin\* or \*zaponex\** in intervention of STUDY) AND (*\*dose\* or \*dosage\* or \*dosage?effect\* or \*dose?activity\* or \*dose?dependence\* or \*dose?effect\* or \*dose?rate\* or \*dose?response\* or \*dosage?scheme\* or \*drug?response\* or \*effective?dose\* or \*dose?finding\* or \*dose?calculation\* or \*therapeutic?equiv\* or \*blood?level\* or \*blood?drug\* or \*serum?level\* or \*serum?drug\* or \*plasma-level\* or \*plasma-drug\* or \*high?dos\* or \*low?dos\* or \*medium?dos\* or \*standard?dos\* or \*middle?dos\* or \*maximum?dos\* or \*minimum?dos\* or \*threshold?dos\** in title abstract and index terms of reference)]

This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see [group module](#)).

##### Searching other resources

#### 1. Reference searching

We searched the reference lists of each included paper, but failed find any new studies.

#### 2. Personal contact

Where possible, we contacted the first author of trials or citations for missing information on unpublished data or trials. Where the first author's contact was not possible through the Cochrane Schizophrenia group, we attempted to contact the other authors. At the time of writing, we have not received any of the missing data we requested, though one author indicated he will send the requested information in future. We have discussed this in detail under relevant sections of results.

## HISTORY

Protocol first published: Issue 1, 2012

Review first published: Issue 6, 2017

Date	Event	Description
8 December 2016	Amended	Search was undertaken and 8 studies (13 references) added to 'Studies awaiting classification' section of the review. One study ( <a href="#">Abraham 1997</a> ) already was in this section from last update.

## CONTRIBUTIONS OF AUTHORS

Selvizhi Subramanian – protocol development, study selection, data collection and synthesis, report writing.

Birgit A Völlm – protocol development, study selection, data collection and synthesis, report writing.

Nick Huband – data synthesis, report writing.

## **DECLARATIONS OF INTEREST**

Selvizhi Subramanian – none known.

Birgit A Völlm – none known.

Nick Huband – none known.

## **SOURCES OF SUPPORT**

### **Internal sources**

- none, Other.

### **External sources**

- none, Other.

## **DIFFERENCES BETWEEN PROTOCOL AND REVIEW**

The original categorisation of doses of clozapine was slightly changed to enable us to accommodate the doses compared in the trials of the four included papers.

## **INDEX TERMS**

### **Medical Subject Headings (MeSH)**

Agranulocytosis [chemically induced]; Antipsychotic Agents [\*administration & dosage] [adverse effects] [supply & distribution]; Clozapine [\*administration & dosage] [adverse effects] [supply & distribution]; Psychotic Disorders [diagnosis] [drug therapy]; Schizophrenia [\*drug therapy]

### **MeSH check words**

Humans